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   With	  over	  30	  different	  Human	  Immunodeficiency	  Virus	  (HIV)	  drugs	  approved	  by	  the	  FDA,	  drug	  
resistance	  is	  still	  a	  major	  problem.	  	  This	  experiment	  suggested	  a	  new	  general	  structure-­‐based	  design	  for	  
drug	   discovery	   based	   on	   the	   substrate	   envelope	   hypothesis	   in	   order	   to	   successfully	   design	   and	  
synthesize	   a	   series	   of	   novel	   HIV-­‐1	   protease	   inhibitors.	   	   The	   design	   inhibitors	   utilize	   the	   2-­‐ethylbutyl	  
group	   as	   new	   high	   affinity	   P1′	   ligands.	   	   The	   designed	   compounds	   showed	   highly	   potent	   inhibitory	  
activity	  against	  wild-­‐type	  and	  a	  panel	  of	  MDR	  HIV-­‐1	  Protease	  variants.	   	   Further	  development	  of	   these	  
protease	  inhibitors	  may	  lead	  to	  more	  effective	  treatments	  against	  drug-­‐resistant	  HIV-­‐1.	  	  	  	  
	  Introduction	  	  
The	  Human	  Immunodeficiency	  Virus	  Pandemic	  (HIV)	  
Since	  the	  United	  States	  declared	  Human	  Immunodeficiency	  Virus	  (HIV)	  a	  pandemic	  in	  1981,	  over	  
30	   HIV	   drugs	   have	   been	   approved	   by	   the	   FDA(1).	   	   Despite	   the	   progress	   of	   these	   drugs,	   56,000	   new	  
infections	  occur	  each	  year	  and	  over	  30	  million	  people	  are	  currently	  affected	  worldwide(2).	  	  By	  2007,	  HIV	  
had	  contributed	   to	  over	  2	  million	  deaths	  with	  565,927	  deaths	   in	   the	  United	  States(2).	   	  Many	  of	   these	  
deaths	  occurred	  in	  developing	  countries,	  where	  major	  societal	  problems	  such	  like	  healthcare,	  nutrition,	  
and	  poverty	  are	  frequently	  encountered(1).	  	  With	  the	  growing	  deaths	  and	  drug	  resistance	  encountered	  
during	  therapy,	  further	  research	  for	  new	  HIV	  drugs	  is	  essential.	  
The	   current	   HIV	   drugs	   used	   to	   treat	   HIV-­‐1	   belong	   to	   four	   classes:	   nucleoside	   and	   nucleotide	  
analogues,	   reverse	   transcriptase	   inhibitors,	   fusion	   inhibitors,	   and	   protease	   inhibitors(3).	   	   A	   common	  
treatment	   of	   HIV	   used	   is	   Highly	   Active	   Antiretroviral	   Treatment	   (HAART),	   which	   is	   a	   combination	   of	  
antiretroviral	  drugs(3).	  	  While	  HAART	  has	  been	  effective	  against	  HIV,	  its	  effectiveness	  is	  decreasing	  due	  
to	   the	   increase	   of	   resistant	  mutations	  within	   the	   virus(2).	   	   Although	   current	   drug	   discovery	   protocols	  
approach	   this	   problem	   by	   testing	   numerous	   analogues,	   this	   approach	   does	   not	   account	   for	   virus	  
mutations	  and	  drug	  resistance(2).	  	  In	  order	  to	  combat	  drug	  resistance,	  new	  inhibitors	  must	  inhibit	  both	  
the	  wild-­‐type	  virus	  and	  mutant	  forms	  of	  HIV(2).	  	  As	  seen	  in	  darunavir,	  which	  is	  the	  most	  potent	  protease	  
inhibitor,	  one	  way	  of	  combating	  resistance	  is	  by	  designing	  drugs	  based	  on	  the	  substrate	  envelope.	  	  With	  
HIV	   recognizing	  various	  substrate	  sequences,	   the	  substrate	  envelope	   is	  a	  conserved	  uniform	  region	  of	  
substrates	  binding	  within	  the	  binding	  site(4).	  	  By	  using	  a	  protease	  inhibitor	  that	  fits	  within	  the	  substrate	  
envelope,	  viral	  resistance	  can	  be	  evaded	  (4).	  	  	  
The	  HIV	  Structure	  	  
	   	  
HIV	   is	  characterized	  as	  a	   retrovirus,	  which	  are	  viruses	   that	  contain	  RNA	  as	   its	  genetic	  material	  
and	  use	   reverse	   transcriptase	   to	  produce	  DNA	   from	   its	  genome	  and	   integrates	   the	  DNA	   into	   the	  host	  
genome	   (1).	   	   HIV	   is	   subgrouped	   with	   lentiviruses,	   which	   replicate	   in	   non-­‐dividing	   cells	   (5).	   	   With	  
lentiviruses,	  serious	  symptoms	  tend	  to	  occur	  after	  a	  long	  period	  from	  the	  initial	  infection	  and	  can	  deliver	  
a	  significant	  amount	  of	  genetic	  information	  to	  the	  DNA	  of	  the	  host	  cell(1).	  
The	  HIV	  envelope	  has	  a	  100	  nm	  diameter	  and	   is	  created	   from	  the	  membrane	  of	  a	  human	  cell	  
during	  the	  budding	  process(1).	  	  Proteins	  are	  fixed	  within	  the	  viral	  envelope	  and	  include	  the	  Env	  protein,	  
which	   protrudes	   from	   the	   surface	   of	   the	   virus(1).	   	   Env	   consists	   of	   glycoprotein	   120	   (gp120)	   and	  
glycoprotein	  41	  (gp41),	  which	  assists	  in	  anchoring	  the	  structure	  to	  the	  viral	  envelope(1).	  	  Within	  the	  viral	  
envelope	  is	  a	  capsid	  that	  surrounds	  two	  strands	  of	  HIV	  RNA(1).	  	  The	  capsid	  is	  made	  up	  of	  2,000	  copies	  of	  
p24,	  a	  viral	  protein(1).	  	  At	  the	  end	  of	  each	  RNA	  are	  long	  terminal	  repeats	  that	  control	  production	  of	  new	  
viruses	  triggered	  by	  proteins	  from	  HIV	  or	  the	  host	  cell(1).	  	  Additionally,	  the	  HIV	  core	  is	  comprised	  of	  p17,	  
an	  HIV	  matrix	  protein,	  and	  p7,	  a	  HIV	  nucleocapsid	  protein	  used	  in	  later	  development	  within	  the	  virus	  life	  
cycle(1).	  
The	  HIV-­1	  Genome	  and	  Life	  Cycle	  	  
HIV-­‐1	   is	  a	  complex	  retrovirus	   that	  encodes	  15	  distinct	  proteins	  and	  express	  nine	  open	  reading	  
frames(6).	  	  The	  gag,	  pol,	  and	  env	  genes	  serve	  to	  produce	  the	  core	  proteins	  necessary	  for	  the	  formation	  
of	  the	  virus.	  	  The	  tat,	  rev,	  nef,	  vif,	  vpr,	  and	  vpu	  genes	  serve	  as	  regulatory	  genes	  to	  control	  reproduction	  
of	  the	  virus(1).	  	  	  	  	  	  
Three	  of	  the	  open	  reading	  frames	  encode	  the	  Gag,	  Pol,	  and	  Env	  polyproteins.	  	  Each	  polyprotein	  
is	  proteolyzed	  into	  individual	  proteins(6).	  	  The	  four	  Gag	  proteins	  (matrix	  (MA),	  capsid	  (CA),	  nucleocapsid	  
(NC),	  and	  p6)	  and	  the	  two	  Env	  proteins	   (surface	  or	  gp120	  (SU)	  and	  transmembrane	  or	  gp41	  (TM))	  are	  
structural	  components	  that	  form	  the	  core	  of	  the	  virion	  and	  outer	  membrane(6).	  	  The	  three	  Pol	  proteins	  
(protease	  (PR),	  reverse	  transcriptase	  (RT),	  and	  integrase	  (IN))	  provide	  the	  essential	  enzymatic	  functions	  
and	  are	   encapsulated	  within	   the	  particle(6).	   	  HIV-­‐1	   also	   encodes	   six	   additional	   	   accessory	  proteins(6).	  	  
Vif,	   Vpr,	   and	   Nef	   and	   are	   found	  within	   the	   viral	   particle,	   while	   Tat	   and	   Rev	   provide	   gene	   regulatory	  
functions,	  while	  Vpu	  indirectly	  aids	  in	  assembling	  the	  virion(6).	   	  The	  retroviral	  genome	  is	  encoded	  by	  a	  
~9	  kb	  RNA	  and	  two	  genomic	  length	  RNA	  molecules	  that	  are	  packaged	  in	  the	  particle(6).	  	  	  
Knowledge	   of	   the	   replication	   cycle	   of	   the	   virus	   is	   essential	   in	   order	   to	   understand	   the	  
mechanism	  of	  action	  for	  antiviral	  drugs	  and	  to	  find	  potential	  drug	  targets	  (Figure	  2).	   	  During	  the	  initial	  
step	  of	  HIV	  replication,	  there	  is	  an	  interaction	  between	  the	  envelope	  proteins	  of	  the	  virus	  (SU),	  the	  cell	  
surface	   receptors	   (CD4	   receptors),	   and	   the	   chemokine	   coreceptors	   (CXCR4	   and	   CCR5)	   of	   the	   host(7).	  	  
This	   initial	   interaction	  causes	  a	  conformational	  change	   in	   the	  envelope	  protein	  and	  promotes	  a	   fusion	  
between	  the	  host	  cytoplasmic	  membrane	  and	  the	  viral	  envelope(7).	  	  This	  fusion	  process	  is	  promoted	  by	  
TM	  and	  allows	  the	  viral	  capsids	  to	  enter	  the	  cell	  through	  the	  membrane(7).	  	  	  
Once	   inside	   the	  membrane,	   the	   virion	   core	   is	   then	   uncoated	   to	   expose	   a	   viral	   nucleoprotein	  
complex	  which	  contains	  MA,	  RT,	  IN,	  Vpr,	  and	  RNA(6).	  	  The	  viral	  DNA	  is	  then	  inserted	  and	  integrated	  into	  
the	  chromosomal	  DNA	  of	  the	  host	  cell	  by	  the	  integrase(7).	  	  The	  IN	  protein	  catalyzes	  the	  intergration	  of	  
the	  viral	  DNA	  into	  a	  host	  chromosome	  and	  the	  DNA	  is	  repaired(6).	  	  The	  expression	  of	  the	  infected	  DNA	  
allows	   for	   production	  of	   precursor	   viral	   proteins(7).	   	   The	   complex	   is	   then	   transported	   to	   the	  nucleus,	  
where	  the	  RNA	  is	  reverse	  transcribed	  by	  RT	   into	  a	  partially	  duplex	   linear	  DNA(6).	   	  The	  viral	   transcripts	  
are	  expressed	  from	  the	  promoter	   located	  in	  the	  5’	  LTR	  with	  Tat	   increasing	  the	  rate	  of	  transcription(6).	  	  
Spliced	  RNAs	  are	  then	  transported	  from	  the	  nucleus	  to	  the	  cytoplasm	  in	  order	  for	  Rev	  to	  regulate	  the	  
translation(6).	  	  	  Once	  the	  viral	  mRNAs	  are	  translated	  in	  the	  cytoplasm,	  the	  Gag	  and	  Gag-­‐Pol	  polyproteins	  
become	   localized	   to	   the	   cell	   membrane	   and	   the	   Env	   mRNA	   is	   translated	   at	   the	   endoplasmic	  
reticulum(6).	  	  The	  Gag	  and	  Gag-­‐Pol,	  Vir,	  Vpr,	  Nef	  and	  genomic	  RNA	  then	  assemble	  the	  core	  particles	  and	  
the	  virion	  begins	  budding	  at	  the	  surface(6).	  	  The	  expression	  of	  the	  infected	  DNA	  allows	  for	  production	  of	  
precursor	  viral	  proteins(7).	  	  	  	  In	  order	  to	  provide	  the	  SU	  and	  TM	  proteins	  for	  the	  outer	  membrane	  	  during	  
budding,	  the	  Env	  polyprotein	  must	  first	  be	  released	  with	  CD4,	  which	  is	  the	  cell	  surface	  HIV-­‐1	  receptor	  in	  
the	  ER(6).	  	  Vpu	  then	  promotes	  the	  CD4	  degradation	  and	  Env	  is	  transported	  to	  the	  cell	  surface	  where	  it	  is	  
prevented	   from	   binding	   CD4(6).	   	   Nef	   facilitates	   the	   routing	   of	   CD4	   from	   the	   cell	   surface	   and	   golgi	  
apparatus	   to	   the	   lysosomes	   and	   results	   in	   receptor	   degradation	   and	  preventing	   interactions	  with	   Env	  
(6).	  	  	  
A	  particle	   is	   released	   from	  the	  cell	   surface	  with	  SU	  and	  TM	  on	   the	  surface	  of	   the	  cell	  and	   the	  
virion	  undergoes	  maturation	  and	  requires	  Vir	  to	  regulate	  the	  proteolytic	  processing	  of	  Gag	  and	  Gag-­‐Pol	  
polyproteins	   by	   the	   protease(6).	   The	   precursor	   viral	   proteins	   which	   are	   assembled	   at	   the	   host	   cell	  
surface,	   form	   new	   viral	   particles,	   and	   leave	   the	   host	   cell	   through	   the	   process	   of	   budding(7).	   	   During	  
budding,	   an	   outer	   layer	   and	   an	   envelope	   are	   acquired	   from	   the	   host	   cell	   and	   the	   protease	   enzyme	  
cleaves	   the	   precursor	   viral	   proteins	   into	   mature	   products(7).	   	   	   If	   the	   protease	   does	   not	   cleave	   the	  
precursor	  proteins	  then	  the	  viral	  particles	  cannot	  initiate	  the	  replication	  cycle	  in	  other	  cells(7).	  	  	  
Comparison	  of	  Potential	  Drug	  Targets	  
HIV	  contains	  many	  enzymes	  and	  receptors	  which	  are	  crucial	  to	  the	  lifecycle	  of	  HIV	  and	  can	  make	  
attractive	  drug	  targets	  including	  integrase(8).	  	  By	  disrupting	  the	  integrase,	  HIV	  cannot	  integrate	  its	  DNA	  
with	   the	   host.	   	   Although	  many	   integrase	   inhibitors	   have	   been	   published	   over	   the	   years,	   no	   integrase	  
inhibitor	  has	  been	  approved	  by	  the	  FDA(9).	   	  Some	  of	  these	  drugs	  have	  made	  clinical	  trials	  and	  most	  of	  
which	  have	   shown	  severe	   liver	  and	  kidney	   toxicity(9).	   	   The	  past	   compounds	  L-­‐870,810	   (Merck)	  and	  S-­‐
1360	  (Shionogi)	  in	  the	  past	  have	  looked	  promising,	  but	  most	  integrase	  inhibitors	  have	  shown	  severe	  liver	  
and	  kidney	  cell	  toxicity(9).	  	  Despite	  these	  toxicity	  issues,	  integrase	  may	  serve	  as	  a	  future	  potential	  drug	  
target.	  
While	  there	  are	  no	   integrase	   inhibitors	  approved	  by	  the	  FDA,	  protease	   inhibitors	  are	  the	  most	  
common	  FDA	  approved	  inhibitors	  and	  the	  reverse	  transcriptase	  inhibitors	  are	  the	  second	  most	  common	  
FDA	   approved	   inhibitors.	   	   Reverse	   transcriptase	   inhibitors	   were	   first	   marketed	   in	   1997	   and	  
revolutionized	   HIV	   therapy	   with	   good	   antiviral	   activity	   and	   convenient	   regimens.	   	   While	   protease	  
inhibitors	   and	   nonnucleoside	   reverse	   transcriptase	   inhibitors	   have	   similar	   potency	   against	   the	   virus,	  
protease	  inhibitors	  are	  more	  effective	  than	  nonnucleoside	  reverse	  transcriptase	  inhibitors	  with	  patients	  
infected	  with	  high	  viral	   loads	   (10).	   	  This	   increase	   in	  effectiveness	   is	  due	  to	  the	  high	  genetic	  barrier	   for	  
resistance	  in	  protease	  inhibitor	  based	  regimens(11).	  	  Protease	  inhibitors	  have	  been	  effective	  for	  treating	  
patients	   with	   an	   interruption	   in	   their	   treatment(12).	   	   Current	   protease	   inhibitors	   have	   not	   been	  
developed	   using	   the	   substrate	   envelope.	   	   By	   design	   protease	   inhibitors	   that	   fit	   within	   the	   substrate	  
envelope	  will	  be	  essential	  for	  future	  HAART	  and	  evading	  viral	  resistance(4).	  	  
Nucleoside	  and	  Nucleotide	  Analogues	  
	   Nucleoside	  and	  nucleotide	  analogues	  act	  as	  DNA	  chain	  terminators	  and	  were	  the	  first	  antiviral	  
drugs	   to	   be	   approved	   for	   treatment	   of	   HIV(7).	   	   This	   class	   of	   HIV	   drugs	   seeks	   to	   inhibit	   reverse	  
transcription	  of	   the	  viral	  RNA	  genome	   into	  DNA	  which	   is	  an	   important	  event	   in	   the	  early	   stage	  of	   the	  
viral	   life	   cycle(3).	   	   The	   nucleoside	   analogs	   refer	   to	   the	   similarity	   of	   nucleic	   acids,	   but	   differ	   by	   the	  
replacement	   of	   a	   hydroxyl	   group	   in	   the	   3’	   position	   and	   by	   adding	   another	   substituent	   incapable	   of	  
forming	  the	  5’	  to	  3’	  phosphodiester	  linkage(3).	  	  DNA	  elongation	  is	  hindered	  by	  the	  incorporation	  of	  the	  
analogue(3).	   	   The	   reverse	   transcriptase	   incorporates	   these	   nucleoside	   and	   nucleotide	   analogues	  
competitively	  into	  the	  viral	  DNA	  	  after	  the	  phosphorylation	  by	  cellular	  kinases(3).	  	  	  	  The	  synthesis	  of	  the	  
viral	  DNA	  is	  then	  stopped	  by	  these	  analogues	  and	  no	  additional	  nucleotides	  can	  be	  added(3).	  	  	  	  	  	  	  
	   Despite	   the	  effectiveness	  of	   these	  drugs,	   several	  mutations	  occur	   in	   the	   reverse	   transcriptase	  
and	   impair	   the	   ability	   of	   the	   reverse	   transcriptase	   to	   incorporate	   an	   analogue	   in	   DNA(3).	   	   The	  most	  
common	   mutations	   that	   occur	   that	   lead	   to	   resistance	   are	   the	   M184V,	   Q151M,	   and	   the	   K65R	  
mutation(3).	   	   Methionine	   184	   is	   located	   at	   the	   active	   site	   of	   the	   catalytic	   region	   of	   the	   reverse	  
transcriptase	   and	   is	   replaced	   by	   a	   valine(3).	   	   The	   M184V	   mutation	   is	   usually	   the	   first	   mutation	   to	  
overtake	  the	  wild-­‐type	  virus	  within	  a	  few	  weeks	  and	  affects	  the	  drug	  lamivudine(3).	  	  The	  different	  side	  
chain	  of	  valine	  interferes	  with	  the	  positioning	  of	  lamivudine	  triphosphate	  analogues	  within	  the	  catalytic	  
site(3).	   	   The	   group	   of	   mutations	   at	   the	   Q151M	   complex	   are	   mutations	   that	   demonstrate	   resistance	  
against	  stavudine	  and	  didanosine(3).	  	  The	  Q151M	  mutation	  affects	  a	  residue	  located	  near	  the	  nucleotide	  
binding	   site	   of	   the	   reverse	   transcriptase(3).	   	   After	   this	   initial	   mutation,	   many	   secondary	   mutations	  
accumulate	  and	  increase	  the	  resistance	  activity	  within	  the	  enzyme(3).	  	  Although	  this	  resistance	  occurs	  in	  
less	  than	  5%	  of	  all	  HIV	  strains	  with	  resistance	  to	  nucleoside	  analogues,	  this	  mutation	  complex	  provides	  
high	   level	   resistance	   to	  most	   	  analogues(3).	   	  The	  K65R	  mutation	  confers	   resistance	   to	  most	  analogues	  
except	  zidovudine	  and	  is	  a	  frequent	  mutation(3).	  	  Despite	  the	  high	  drug	  resistance	  encountered	  against	  
HIV,	  nucleoside	  and	  nucleotide	  analogues	  are	  essential	  to	  HAART	  therapy.	  	  	  
Nonnucleoside	  Reverse	  Transcriptase	  Inhibitors	  
Nonnucleoside	   reverse	   transcriptase	   inhibitors	   bind	   noncompetitively	   and	   inhibit	   reverse	  
transcriptase(3).	  	  These	  inhibitors	  bind	  to	  the	  reverse	  transcriptase	  enzyme	  and	  block	  activity	  at	  the	  DNA	  
polymerase	   by	   causing	   a	   conformational	   change	   and	   disrupting	   the	   catalytic	   site(7).	   	   Nonnucleoside	  
reverse	   transcriptase	   inhibitors	   do	   not	   require	   phosphorylation	   to	   become	   active	   and	   are	   not	  
incorporated	  into	  the	  DNA(7).	  	  By	  affecting	  the	  flexibility	  of	  the	  enzyme,	  the	  binding	  of	  the	  inhibitors	  is	  
blocked	  and	  the	  reverse	  transcriptase	  is	  unable	  to	  synthesize	  DNA(3).	  	  
	   Most	   of	   the	   mutations	   that	   occur	   with	   nonnucleoside	   reverse	   transcriptase	   inhibitors	   are	  
located	   in	   the	   pocket	   target,	   which	   reduce	   the	   affinity	   of	   the	   drug(3).	   	   The	   subtle	   differences	   in	   the	  
interactions	   between	   the	   various	   nonnucleoside	   reverse	   transcriptase	   inhibitors	   and	   the	   hydrophobic	  
pocket	  often	  cause	  mutations	  at	  Y181C,	  Y188C,	  K103N,	  G190A,	  and	  V106A(3).	  	  	  
Fusion	  Inhibitors	  	  
	   The	  HIV	  membrane	  contains	  gp120,	  and	  gp41(7).	   	   In	   the	  envelope	  structure,	  gp120	  molecules	  
make	   up	   the	   cap,	   gp41	   forms	   the	   stalk	   and	   it	   is	   anchored	   by	   the	   viral	   lipid	   bilayer(7).	   	   By	   utilizing	   a	  
sequence	   of	   interactions	   between	   the	   glycoprotein	   complex	   (gp120-­‐gp41)	   and	   specific	   cell	   surface	  
receptors,	  HIV-­‐1	   can	  enter	   target	   cells	   through	  a	   conformational	   change	   in	   gp41(3).	   	  During	   the	  early	  
stages	  of	  this	  process,	  two	  motifs	  from	  gp41	  interact	  with	  the	  heptad	  repeat(HR)	  1	  and	  2	  and	  unite	  to	  
form	  a	  6-­‐helix	  hairpin	  bundle	  structure	  in	  order	  to	  attach	  	  the	  virus	  to	  the	  target(7).	  	  The	  membrane	  of	  
the	  virus	  and	  the	  target	  are	  brought	  close	  together	  and	  fused	  by	  rearranging	  gp41(3).	  	  The	  hydrophobic	  
region	  of	  gp41,	  HR2,	   folds	  onto	  a	  proximal	  hydrophobic	   region,	  HR2,	  which	   shortens	   the	  molecule(3).	  	  
The	  only	   FDA	  approved	   fusion	   inhibitor	   is	   Enfuvirtide,	  which	   is	   a	   36	   amino	  acid	  peptide	  derived	   from	  
HR2.	   	   Enfuviritide	   binds	   to	   the	   HR1	   region	   of	   gp41	   and	   blocks	   the	   formation	   of	   the	   6	   helix	   bundle	  
necessary	  for	  fusion.	  	  Destabilizing	  HR1	  binding	  prevents	  HIV	  from	  affecting	  the	  target(3).	  
	   Viral	   resistance	  usually	   occur	   from	  mutations	   that	   are	   located	   in	   a	   stretch	  of	   ten	   amino	   acids	  
within	   HR1(3).	   	   Changes	   to	   the	   amino	   acids	   in	   gp41	   and	   gp120	   outside	   HR1	   are	   associated	   with	  
significant	  differences	  in	  the	  effectiveness	  of	  Enfuvirtide(3).	  	  
Highly	  Active	  Antiretroviral	  Treatment	  (HAART)	  
	   In	   1996,	   Highly	   Active	   Antiretroviral	   Treatment	   (HAART)	   became	   available	   and	   was	   effective	  
because	   it	   would	   combine	   multiple	   mechanisms	   and	   drugs	   in	   order	   to	   avoid	   resistance(3).	   	   The	  
development	   of	   HAART	   transformed	   a	   fatal	   disease	   into	   a	   chronic	   and	   manageable	   disease(8).	   	   The	  
strategy	  used	  by	  HAART	  involves	  multiple	  mechanisms	  for	  virus	  inhibition(3).	   	  The	  probability	  that	  that	  
these	  mutants	  would	  be	  able	   to	   resist	  all	  of	   the	  drugs	   in	   the	   regimen	  would	  be	  much	   lower	   than	  any	  
single	  drug	  alone(3).	  	  Currently	  there	  are	  four	  classes	  of	  inhibitors:	  nucleoside	  and	  nucleotide	  analogues,	  
reverse	  transcriptase	  inhibitors,	  fusion	  inhibitors,	  and	  protease	  inhibitors(3).	  	  	  
The	  HIV-­1	  Protease	  
	   The	  HIV-­‐1	  protease	  is	  encoded	  in	  the	  viral	  Pro	  gene,	  which	  is	  downstream	  of	  the	  gag	  gene	  and	  
upstream	  from	  the	  pol	  gene	  and	  is	  expressed	  as	  the	  polyprotein	  precursor	  Gag-­‐Pro-­‐Pol(8).	  	  In	  order	  for	  
HIV	   to	   become	  active,	   the	  Gag-­‐Pro-­‐Pol	   precursor	  must	   dimerize	   in	   order	   for	  HIV	  protease	   to	  become	  
active(8).	  	  Although	  little	  is	  known	  about	  how	  the	  protease	  excises	  itself	  from	  the	  polyprotein	  precursor,	  
the	  initial	  cleavage	  occurs	  in	  cis	  at	  a	  novel	  cleavage	  site(8).	  
	   HIV-­‐1	  protease	  is	  a	  homodimeric	  aspartyl	  protease	  with	  its	  active	  site	  at	  the	  dimer	  interface	  with	  
two	   aspartic	   acids	   located	   at	   the	   base	   of	   the	   active	   site(8).	   	   The	   enzymatic	  mechanism	   is	   a	   push	  pull	  
mechanism	  with	  an	  acid-­‐base	  catalysis	  with	  a	  water	  molecule(8).	  	  The	  water	  molecule	  transfers	  a	  proton	  
to	   the	   carboxyl	   groups	   of	   the	   aspartic	   acids	   and	   then	   is	   transferred	   to	   the	   targeted	   cleaved	   peptide	  
bond(8).	  	  During	  this	  process,	  a	  non-­‐covalent	  tetrahedral	  intermediate	  is	  briefly	  formed	  (Figure	  3,Figure	  
4)(8,	  13).	  	  A	  mobile	  beta	  turn	  serves	  as	  a	  flap	  to	  cover	  the	  active	  site	  within	  each	  subunit(8).	  	  In	  order	  for	  
the	  substrate	  to	  have	  access	  to	  the	  active	  site,	  the	  flaps	  must	  be	  able	  to	  move	  away	  (Figure	  5)	  (8).	  	  Once	  
the	  substrate	  is	  recognized	  and	  bound,	  the	  flaps	  must	  move	  over	  the	  active	  site	  and	  lock	  down	  over	  the	  
bound	   substrate.	   	   This	   step	   completes	   the	   active	   site	   cavity	   and	   permits	   substrate	   cleavage(8).	   	   The	  
turnover	  number	  (Kcat)	  for	  the	  HIV	  protease	  dimer,	  which	  is	  the	  number	  of	  enzymatic	  reactions	  per	  unit	  
time,	  is	  4.9	  s-­‐1(14).	  	  The	  Michaelis	  constant,	  Km,	  is	  the	  approximate	  affinity	  for	  enzyme	  to	  substrate(14).	  	  
A	   small	   Km	   means	   Vmax	   has	   reached	   a	   low	   concentration	   of	   substrate	   and	   approximately	   indicates	  
increased	   binding	   affinity	   to	   the	   substrate(14).	   	   The	  measured	   Km	   for	   the	  HIV	   protease	   from	   another	  
experiment	  was	  103	  µM	  and	  the	  Vmax	  was	  164	  nM	  min
-­‐1.	  	  	  	  	  
	   HIV	   protease	   cleaves	   the	  Gag	   and	  Gag-­‐Pro-­‐Pol	   polyproteins	   at	   ten	   sites	   and	   the	   cleavage	   site	  
recognize	   eight	   different	   substrates	   throughout	   the	   P4’	   and	   P4	   pockets(8).	   	   These	   ten	   sites	   are	   quite	  
diverse	  and	  are	  cleaved	  with	  different	  efficiencies(8).	  	  Despite	  these	  differences,	  most	  of	  these	  substrate	  
sites	   contain	   many	   common	   characteristics	   such	   as	   a	   branched	   amino	   acid	   residue	   at	   the	   P2	   site,	   a	  
hydrophobic	   residue	   at	   the	   P1	   site,	   and	   an	   aromatic	   or	   proline	   at	   the	   P1’	   site(8).	   	   However,	   the	  
difference	   in	  substrate	  sequences	  result	   in	  variation	  of	  cleavage	  rates	  and	  contribute	  to	   the	  order	   the	  
substrates	  are	  cleaved(8).	  
Development	  of	  Resistance	  
	   The	   high	   levels	   of	   virus	   production	   along	   with	   the	   low	   fidelity	   rate	   of	   the	   HIV’s	   reverse	  
transcriptase	   results	   in	   a	   development	   of	   diverse	   viral	   mutations	   which	   can	   infect	   target	   cells	   at	   an	  
extremely	  rapid	  rate	  (3).	   	  During	  transcription,	  the	  reverse	  transcriptase	   is	  error	  prone	  with	  mutations	  
averaging	  one	  mutation	  per	  viral	  genome	  transcribed(3).	   	  The	  reverse	  trasnscriptase	   is	   responsible	   for	  
making	  a	  double	  stranded	  DNA	  copy	  from	  a	  single	  stranded	  RNA	  template	  molecule;	  however,	  reverse	  
transcriptase	   has	   no	   proofreading	   ability(15).	   	   While	   substitution	   is	   the	   most	   common	   error,	  
duplications,	   insertions,	   and	   recombination	   also	   frequently	   occur(3).	   	  When	   under	   selective	   pressure,	  
even	   a	   single	   substitution	   of	   an	   amino	   acid	   can	   produce	   high	   levels	   of	   resistance	  within	   a	  matter	   of	  
weeks(3).	  	  In	  fact,	  nearly	  70%	  of	  99	  residues	  in	  HIV-­‐1	  protease	  are	  known	  to	  mutate(8).	  	  	  	  	  	  	  	  	  	  
The	  Substrate	  Envelope	  Hypothesis	  
The	  conserved	  shape	  substrates	   that	  adopt	  within	   the	  active	   site	  of	   the	  protease	   is	   called	   the	  
substrate	  envelope	  (Figure	  6)	  (8).	  	  The	  protease	  recognizes	  different	  substrates	  based	  on	  shape,	  rather	  
than	   a	   specific	   amino	   acid	   sequence(4).	   	   Key	   points	   of	   resistance	   tend	   to	   occur	   in	   clusters	  when	   the	  
inhibitors	   protrude	   outside	   of	   the	   substrate	   envelope(4).	   	   This	   can	   be	   seen	  when	   superimposing	   the	  
substrate	   envelope	   and	   the	   inhibitor	   envelope,	   which	   is	   the	   volume	   occupied	   by	   the	   overlapped	  
inhibitors	   (Figure	  7)	   (16).	   	  As	   seen	   in	   Figure	  7,	   the	   inhibitor	  envelope	  protrudes	  outside	   the	   substrate	  
envelope	   perhaps	   explaining	  why	   current	   drugs	   face	   drug	   resistance.	   	   However,	  when	   superimposing	  
the	  substrate	  envelope	  with	  darunavir,	  there	  is	   little	  resistance	  encountered	  (Figure	  8).	   	  By	  developing	  
an	   inhibitor	   that	   fits	   within	   this	   uniform	   region,	   the	   inhibitor	   would	   be	   more	   likely	   to	   evade	   viral	  
resistance	   (4).	   	   A	  mutation	   that	  would	   affect	   inhibitor	   binding	  would	   also	   reduce	   the	   affinity	   for	   the	  
substrate,	  preventing	  HIV’s	  propagation(4).	  	  By	  using	  the	  substrate	  envelope	  as	  a	  basis	  for	  drug	  design,	  
drug	  resistance	  for	  mutations	  should	  be	  less	  likely,	  since	  these	  enzymes	  must	  allow	  the	  substrate	  to	  bind	  
in	  order	  to	  propagate(4).	  	  	  
Protease	  Inhibitors	  
	   HIV-­‐1	  protease	  is	  a	  complex	  enzyme	  with	  2	   identical	  halves	  and	  its	  active	  site	   is	   located	  at	  the	  
base	  of	  the	  cleft(7).	   	  The	  HIV-­‐1	  protease	  cleaves	  the	  large	  viral	  precursor	  polypeptide	  chains	  into	  small	  
and	   functional	   proteins,	   allowing	   HIV	   to	   propagate(7).	   	   However,	   by	   creating	   low	   molecular	   weight	  
molecules	  that	  tightly	  fit	  into	  the	  HIV	  protease,	  HIV	  replication	  is	  hindered(17).	  
Currently	  there	  are	  nine	  FDA	  approved	  protease	   inhibitors:	  saquinavir	   (1995),	   ritonavir	   (1996),	  
indinavir	  (1996),	  nelfinavir	  (1997),	  amprenavir	  (1999),	  lopinavir	  (2000),	  atazanavir	  (2003),	  fosamprenavir	  
(2003),	  tipranavir	  (2005),	  and	  darunavir	  (2006)(8).	  	  The	  inhibitors	  are	  competitive	  active	  site	  that	  bind	  to	  
the	  protease	  from	  the	  nanomolar	  to	  picomolar	  range(8).	  	  Despite	  the	  many	  protease	  inhibitors	  over	  the	  
last	  decade,	  there	  is	  a	  need	  for	  more	  potent	  inhibitors	  with	  improved	  pharmacokinetics,	  decreased	  side	  
effects,	  and	   increased	  effectiveness	  against	  mutant	  HIV	  proteases(8).	   	  Many	  of	  the	  protease	   inhibitors	  
have	  closely	  overlapping	  structures	  and	  interactions(8).	  	  	  
Seven	  of	  the	  nine	  inhibitors	  are	  peptidomimetics,	  which	  are	  small	  proteins	  designed	  to	  mimic	  a	  
peptide	  and	  	  to	  mimic	  the	  enzymatic	  transition	  state(8).	  	  The	  enzymatic	  transition	  state	  contains	  several	  
noncleavable	  dipeptide	  isosteres	  to	  mimic	  the	  transition	  state	  of	  substrate	  cleavage(8).	  	  These	  inhibitors	  
fit	   into	   the	   P2-­‐P2’	   region	   of	   the	   active	   site	   with	   a	   hydrophobic	   cyclical	   side	   chain	   at	   P1	   and	   a	   bulk	  
functional	  group	  at	  P1’	  region(8).	   	  Many	  of	  the	  drugs	  contain	   large	  hydrophobic	  moieties	  that	   interact	  
with	  the	  hydrophobic	  P2-­‐P2’	  pocket	  in	  the	  active	  site(17).	  	  However,	  Tipranavir	  is	  an	  exception	  and	  has	  
demonstrated	   potent	   inhibition	   against	   clinical	   isolates	   resistant	   to	   multiple	   inhibitors	   due	   to	   its	  
molecular	   flexibility	   and	   allows	   tipranavir	   to	   fit	   in	   the	   active	   site	   of	   the	   protease	   that	   has	   become	   to	  
resistant	   to	   other	   protease	   in	   inhibitors(8).	   	   Darunavir	   is	   the	   second	   nonpeptidic	   protease	   inhibitor,	  
replacing	  the	  tetrohydrofuranyl	  (THF)	  with	  a	  bis-­‐THF	  component(8).	  	  	  
Resistance	  to	  Protease	  Inhibitors	  
	   While	  protease	   inhibitors	  have	  strong	  affinity	   for	   the	  active	  site,	   resistance	  can	  emerge	  within	  
the	   substrate	   binding	   site	   of	   the	   protease	   (Figure	   9)	   (3).	   	   Mutations	   allow	   the	   protease	   variant	   to	  
maintain	   its	   function	   by	   cleaving	   10	   natural	   substrates	   in	   the	   Gag	   and	   Gag-­‐Pro-­‐Pol	   polyproteins(17).	  	  
Amino	   acid	   changes	   however	   can	   reduce	   the	   affinity	   for	   most	   binding	   inhibitors	   because	   they	   can	  
modify	   the	   number	   and	   points	   of	   contact	   between	   the	   inhibitors	   and	   protease(3).	   	  When	   comparing	  
protease	  inhibitors	  to	  the	  natural	  substrates,	  inhibitors	  tend	  to	  fit	  tighter	  and	  occupy	  more	  space	  within	  
the	   active	   site(3).	   	   However,	   inhibitors	   tend	   to	   be	   smaller	   than	   substrates	   in	   order	   to	   maintain	  
bioavailability	  and	  have	  a	  different	  shape	  than	  the	  substrates(17).	  	  Natural	  substrates	  are	  less	  tight	  and	  
more	   variable	   and	   allows	   for	   cleavage	   of	   the	   polyproteins	   required	   for	   proper	   assembly	   of	   the	   viral	  
particle(3).	  	  Substitutions	  of	  amino	  acids	  near	  the	  cleavage	  sites	  of	  the	  gag	  polyprotein	  increase	  the	  level	  	  
of	  resistance	  and	  explicative	  capacity	  of	  HIV(3).	  	  However,	  only	  34	  of	  99	  residues	  of	  HIV-­‐1	  protease	  have	  
had	  clinical	  significance(17).	  	  	  
The	  most	   common	  multidrug	   resistant	   variants	  are	  M1	   (L10I,	  G48V,	   I54V,	   L63P,	  V82A)	   (Figure	  
10),	  M2	  (D30N,	  L63P,	  N88D),	  M3	  (L10I,	  L63P,	  A71V,	  G73S,	  184V,	  L90M)	  (Figure	  11),	  and	  M4(I50V,	  A71V)	  
(Figure	  12)	  (18).	  	  The	  M1	  variant	  is	  resistant	  to	  nelfinavir	  and	  the	  M4	  variant	  is	  resistant	  to	  amprenavir	  
and	   darunavir(18).	   	   However,	   the	  mutations	   D30N,	   G48V,	   V82A,	   I84V,	   I50V,	   and	   I50L	   affect	   inhibitor	  
binding	  by	   altering	   specific	   points	  within	   the	   active	   site(17).	   	  D30N	   is	   a	   common	  mutation	   associated	  
with	  nelfinavir;	  G48V	  is	  a	  common	  mutation	  for	  saquinavir;	  I50V	  is	  a	  common	  mutation	  associated	  with	  
amprenavir	  and	  darunavir;	  I50L	  is	  a	  common	  mutation	  with	  atazanavir;	  V82A	  and	  I84V	  affect	  the	  binding	  
of	  all	  inhibitors(17).	  	  	  
There	   are	   also	   mutations	   that	   alter	   the	   balance	   between	   substrate	   recognition	   and	   inhibitor	  
binding(17).	  	  By	  increasing	  the	  flexibility	  of	  the	  HIV-­‐1	  protease,	  it	  may	  affect	  the	  inhibitor	  by	  increasing	  
the	   rate	  of	  dissociation	  between	   the	  protease	  and	   the	   inhibitor(17).	   	  When	   looking	  at	  HIV-­‐1	  patients,	  
only	   five	  to	   fifteen	  mutations	  are	   found	  on	  the	  protease	  gene	  with	  mutations	  both	   inside	  and	  outside	  
the	  active	   site(17).	   	  Common	  outside	  mutations	   include	  L10I,	   I54V,	   I54T,	  A71V,	  A71T,	  V77I,	  and	  L90M	  
and	  these	  mutations	  not	  only	  affect	  inhibitor	  binding,	  but	  also	  compensate	  for	  viability	  and	  fitness	  of	  the	  
enzyme(17).	  	  When	  overlaying	  most	  protease	  inhibitors	  over	  the	  substrate	  envelope,	  many	  of	  protease	  
inhibitors	  protrude	  beyond	  the	  substrate	  envelope	  at	  the	  P3	  and	  P2’	  subsites(16).	  	  	  
Optimizing	  the	  Protease	  Inhibitors	  
	   Two	  characteristics	  for	  an	  effective	  protease	  inhibitor	  are	  having	  high	  potency	  on	  both	  the	  wild-­‐
types	   and	   having	   a	   broad	   range	   of	   drug	   resistant	   strains(19).	   	   Protease	   inhibitors	   also	   must	   have	  
favorable	   pharmacokinetic	   properties	   such	   as	   oral	   administration(19).	   	   Prior	   to	   darunavir,	   most	  
discovery	   teams	   focused	   on	   optimizing	   for	   wild-­‐type	   potency	   rather	   than	   compounds	   effective	   on	  
resistant	  strains(19).	  	  The	  binding	  affinity	  of	  Darunavir	  was	  found	  to	  be	  much	  higher	  than	  other	  analyzed	  
protease	  inhibitors	  and	  has	  been	  shown	  to	  fit	  well	  within	  the	  substrate	  envelope(8).	  	  	  
Due	   to	   the	   high	   binding	   affinity	   and	   effectiveness	   against	   resistant	   strains,	   structure	   activity	  
relationship	  should	  be	  analyzed	  in	  order	  to	  optimize	  analogues	  of	  darunavir.	  	  Darunavir	  contains	  the	  bis-­‐
THF	  moiety	  for	  improved	  interaction	  in	  the	  P2’-­‐pocket(19).	   	  The	  additional	  hydrogen	  bonding	  between	  
bis-­‐THF	  ring	  and	  protease	  inhibitor	  backbone	  results	  in	  activity	  against	  a	  broad	  range	  of	  clinical	  isolates	  
with	   an	   IC50	   in	   the	   nanomolar	   range	   including	  multidrug	   resistant	   HIV-­‐1(8).	   	  When	   introducing	   the	  p-­‐
nitro,	  p-­‐acetyl,	   and	  p-­‐iodo	  groups,	   the	  withdrawing	   substituent	  groups	  on	  darunavir	  did	  not	   influence	  
the	   potency	   on	   the	   wild-­‐type	   virus.	   	   However,	   changing	   the	   substituent	   groups	   has	   demonstrated	  
increased	  activity	  in	  the	  mutant	  viruses(19).	  
When	   looking	   at	   the	   most	   effective	   protease	   inhibitors,	   the	   NH	   interaction	   with	   Asp30	   was	  
found	   in	   the	  compounds	  with	   the	  highest	  activity	  on	   the	  wild-­‐type	  enzyme(19).	   	   The	  backbone	  NH	  of	  
Asp30’	  also	  forms	  a	  hydrogen	  bond	  with	  the	  bond	  accepting	  groups	  substituted	  on	  the	  benzene	  ring(19).	  	  
Since	  the	  scaffold	  was	  anchored	  by	  hydrogen	  bonds	  to	  the	  aspartyl	  dyad,	   the	  positions	  of	  a	  variety	  of	  
substituent	   groups	   can	   be	   predicted	   in	   the	   target	   subsites(20).	   	   This	   was	   due	   to	   the	   nature	   of	   the	  
arrangement	  of	   lone	  pairs	   in	  the	  substituent	  group	  and	   leading	  to	  a	  stronger	   interaction	  and	   is	  crucial	  
against	  the	  wild-­‐type	  protease(19).	  	  The	  position	  of	  the	  oxygen	  atoms	  might	  also	  influence	  the	  presence	  
of	   van	   der	  Waals	   interactions	   of	   the	  methyl	   group	   side	   chains	   present	   in	   the	   P2’	   pocket(19).	   	   Other	  
essential	  substituent	  groups	  are	  the	  p-­‐NH2,	  p-­‐OH,	  and	  p-­‐CH2NH2,	  which	  form	  a	  hydrogen	  bond	  with	  the	  
backbone	  of	  the	  carboxylic	  acid	  of	  Asp30(19).	  	  Another	  water	  mediated	  hydrogen	  bond	  was	  also	  forms	  
with	  the	  side	  chain	  of	  Asp30	  in	  the	  P2’	  pocket(19).	  	  	  
While	  the	  first	  generation	  of	  protease	   inhibitors	  binding	  to	  the	  HIV	  protease	   is	  mainly	  entropy	  
driven,	  new	  protease	  inhibitors	  are	  both	  entropy	  and	  enthalpy	  driven(19).	  	  The	  enthalpic	  driven	  binding	  
contributes	   to	   the	   tight	   interactions	   between	   the	   inhibitor	   and	   the	   enzyme(19).	   	   The	   affinity	   to	  
backbone	   interactions	   allow	   the	   protease	   inhibitor	   to	   retain	   their	   wild-­‐type	   potency(19).	   	   Unlike	   the	  
newer	   protease	   inhibitors,	   the	   first	   generation	   protease	   inhibitors	   do	   not	   fit	   well	   in	   the	   substrate	  
envelope	  and	  resistance	  is	  encountered	  at	  positions	  that	  protrude	  beyond	  the	  substrate	  envelope(19).	  	  
Testing	  For	  Drug	  Resistance	  
	   The	  HIV	  protease	  allows	   for	   correct	  processing	  of	   viral	  polyproteins	  and	  maturation	  of	  HIV	  by	  
cleaving	   the	   polyproteins(14).	   	   In	   order	   to	   identify	   the	   effectiveness	   of	   protease	   inhibitors,	   an	   assay	  
based	   on	   intramolecular	   fluorescence	   resonance	   energy	   transfer	   (FRET)	   can	   allow	   for	   a	   quick	   and	  
practical	  method	  for	  screening	  large	  number	  of	  inhibitors(14).	  	  The	  natural	  substrate	  of	  HIV	  protease	  can	  
be	   covalently	   labeled	  with	   the	   donor	   and	   acceptor(21).	   	   The	   energy	   transfer	   between	   the	   donor	   and	  
acceptor	  occurs	  due	  to	  long	  range	  dipole-­‐dipole	  interactions(21).	  	  	  
The	   specific	   assay	   used	   fluorgenic	   substrates	   4-­‐(4-­‐dimethyaminophenylazo)benzoic	   acid	  
(DABCYL)	   and	   Ser	   Gln	   Asn	   Tyr	   Pro	   Ile	   Val	   Gln-­‐5[(2-­‐aminoethyl)amino]naphthalene-­‐1	   sulfonic	   acid	  
(EDANS)	  (Figure	  13)	  (14).	  	  EDANS,	  which	  attaches	  at	  the	  C	  terminus,	  	  is	  a	  fluorescent	  donor	  and	  DABCYL,	  
which	   attaches	   to	   the	  N	   terminus,	   is	   a	   non-­‐fluorescent	   quenching	   acceptor	   (Figure	   14)	   (14).	   	   Prior	   to	  
cleavage	   from	   the	   protease,	   the	   fluorescence	   in	   EDANS	   is	   reduced	   significantly	   due	   to	   intramolecular	  
resonance	   energy	   transfer	   (RET)	   with	   DABCYL(14).	   	   Since	   RET	   is	   no	   longer	   significant	   after	   100	   Å,	  
fluorescent	   activity	   of	   EDANS	   is	   restored	   after	   cleavage	   from	   the	   protease	   and	   liberation	   from	   the	  
DABCYL	  peptide	  fragment(14).	   	  By	  measuring	  the	   initial	  velocity	  of	  the	  fluorescence	  activity	  over	  time,	  
the	   effectiveness	   of	   protease	   inhibitors	   can	   be	   analyzed;	   an	   decrease	   in	   fluorescence	   suggests	   a	  
decrease	  in	  protease	  activity(14).	  	  After	  measuring	  the	  initial	  velocity,	  the	  Ki	  values	  were	  calculated	  using	  
the	  Morrison	  equation(18).	  	  Since	  these	  HIV	  protease	  inhibitors	  have	  picomolar	  Ki	  values,	  the	  Morrison	  
allows	  for	  precise	  and	  accurate	  calculation	  of	  inhibitor	  binding.	  	  	  
Drug	  Discovery	  and	  Future	  Protease	  Inhibitors	  
Many	  of	  the	  initial	   leads	  for	  the	  HIV	  protease	  inhibitors	  were	  found	  within	  the	  pharmaceutical	  
companies	  libraries	  which	  were	  originally	  designed	  for	  aspartyl	  protease	  renin(8).	  	  Structure	  based	  drug	  
design	  was	  then	  used	  to	  optimize	   inhibitor	  design	  and	  many	   laboratories	  would	  cocrystallize	  patented	  
compounds(8).	   	   With	   these	   patented	   compounds,	   other	   laboratories	   would	   determine	   find	   out	  
alternative	   scaffolds	   that	   would	   preserve	   the	   same	   contacts	   but	   with	   better	   pharmacokinetics	   and	  
bioavaibility(8).	   	   	   Protease	   inhibitors	   that	   fit	  within	   the	   substrate	  envelope	   can	  also	  be	  discovered	  via	  
computational	   design	   and	  by	  using	   quantitative	   structure	   activity	   relationship	   (QSAR)(2).	   	  Using	  QSAR	  
and	  protein	  crystallography	  is	  a	  simple	  and	  practical	  way	  of	  using	  binding	  affinity	  data	  for	  the	  design	  of	  
new	  HIV	  protease	  inhibitors(2).	  	  	  	  	  
	   When	   compared	   to	   previous	   protease	   inhibitors,	   darunavir	   fits	   better	   into	   the	   substrate	  
envelope,	   encounters	   less	   drug	   resistance	   than	   previous	   inhibitors,	   and	   shows	   higher	   binding	  
affinity(17).	   	  While	  current	  strategies	   focus	  on	  analyzing	   failure	  modes	  of	  existing	  drugs	  and	  designing	  
new	  compounds	  with	  high	  efficiency	  against	  known	  mutants,	  many	  of	  these	  drugs	  encounter	  new	  and	  
unanticipated	  modes	  of	  resistance(18).	  	  By	  using	  structure	  activity	  relationship	  (SAR)	  and	  computational	  
methods,	   tight	   binding	   inhibitors	   that	   are	   not	   susceptible	   to	   escape	   mutations	   even	   when	   specific	  
mutations	  are	  unknown	  need	  to	  be	  designed(17).	  
	  Materials	  and	  Methods	  
Synthesis	  of	  the	  HIV-­1	  Protease	  Inhibitors	  
Synthesis	  of	  tert-­butyl	  (2S,3S)-­4-­(2-­ethylbutylamino)-­3-­hydroxy-­1-­phenylbutan-­2-­
ylcarbamate	  (KY-­15)	  
	  
Ring	  Opening	  of	  Epoxide	  	  
	  
Procedure:	  
To	   a	   solution	   of	   the	   chiral	   epoxide,	   (1S,	   2S)-­‐(1-­‐oxiranyl-­‐2-­‐phenylethyl)	   carbamic	   acid	   tert-­‐butyl	   ester	  
(7.89,	   30	   mmol),	   in	   EtOH	   (100	   ml)	   was	   added	   to	   2-­‐ethylbutanol-­‐1-­‐amine	   (3.04	   g,	   30	   mmol)	   and	   the	  
mixture	   was	   heated	   at	   85°	   C	   for	   3	   hours.	   	   After	   the	   solution	   was	   cooled	   to	   room	   temperature,	   the	  
solvent	  was	  removed	  under	  pressure.	  	  The	  product	  was	  then	  purified	  by	  recrystallization	  from	  an	  EtOAC-­‐
hexanes	  (1:10)	  mixture	  and	  provided	  the	  product	  as	  a	  white	  solid	  (5.09,	  46.5%).	  
Synthesis	  of	  tert-­butyl	  (2S,3R)-­4-­(N-­(2-­ethylbutyl)-­4-­methoxyphenylsulfonamido)-­3-­
hydroxy-­1-­phenylbutan-­2-­ylcarbamate	  (KY-­17)	  
	  




To	  an	  ice	  cooled	  solution	  of	  the	  above	  secondary	  amine,	  KY-­‐15	  (1.82	  g,	  5	  mmol),	  in	  CH2Cl2	  (50	  mL)	  was	  
added	  to	  an	  aqueous	  solution	  of	  Na2CO3	  (0.848	  g,	  8	  mmol	  in	  20	  mL	  of	  H2O)	  followed	  by	  the	  slow	  addition	  
of	  4-­‐methylphenylsulfonylchloride	  solid	  (1.07	  g,	  5.20	  mmol).	  	  After	  15	  minutes,	  the	  reaction	  mixture	  was	  
warmed	  to	  room	  temperature	  and	  stirred.	   	  No	  starting	  material	  was	  detected	  by	  TLC	  and	  the	  reaction	  
mixture	  was	  diluted	  with	  CH2Cl2	  and	  the	  organic	  layer	  extract	  was	  collected.	  	  After	  collecting	  the	  organic	  
layer,	   the	   extract	  was	  dried	  with	  Na2SO4,	   filtered,	   and	  evaporated	  under	   reduced	  pressure.	   	  Using	   an	  
EtOAc-­‐hexanes	   (1:4)	  mixture	  as	   an	  eluent,	   the	   residue	  was	  purified	  by	   flash	   chromatography	  on	   silica	  
gel.	   	  This	  provided	  a	  product	  (2.35	  g,	  87.9%)	  as	  a	  white	  foamy	  solid.	   	  After	  the	  H1	  NMR	  was	  taken,	  the	  
residue	  was	  again	  purified	  by	  flash	  chromatography	  on	  silica	  gel	  using	  an	  EtOAc-­‐hexanes	  mixture	  (1:4)	  as	  
an	  eluent.	  	  This	  provided	  a	  pure	  product,	  KY-­‐17	  (1.94	  g,	  72.6%),	  as	  a	  foamy	  white	  solid.	  	  	  
1H	  NMR	  (400	  MHz,	  CDCl3)	  δ	  7.72-­‐7.69	  (m,	  2H),	  7.32-­‐7.19	  (m,	  5H),	  6.99-­‐6.96	  (m,	  2H),	  3.97	  (br	  s,	  1H),	  3.90	  
(s,	  3H),	  3.75	  (s,	  3H),	  3.11-­‐2.98	  (m,	  4H),	  2.93-­‐2.81	  (m,2H),	  1.46-­‐1.38	  (m,	  2H),	  1.33	  (s,	  9H),	  1.29-­‐1.24	  (m,	  
3H),	  0.84-­‐0.79	  (m,	  6H).	  	  	  
Synthesis	  of	  tert-­butyl	  (2S,3R)-­4-­(N-­(2-­ethylbutyl)benzo[d][1,3]dioxole-­5-­sulfonamido)-­3-­
hydroxy-­1-­phenylbutan-­2-­ylcarbamate	  (KY-­19)	  
	  
Synthesis	  of	  (R)-­‐(hydroxyethylamino)sulfonamides	  
KY-­‐15	   KY-­‐17	  
	  Procedure:	  
To	  an	  ice	  cooled	  solution	  of	  the	  above	  secondary	  amine,	  KY-­‐15	  (2.19	  g,	  6	  mmol)	   in	  CH2Cl2	  (50	  mL)	  was	  
added	   to	   an	   aqueous	   solution	   of	   Na2CO3	   (1.4	   g,	   13.2	   mmol	   in	   20	   mL	   of	   H2O)	   followed	   by	   the	   slow	  
addition	  of	  1,3-­‐benzodioxole-­‐5-­‐sulfonylchloride	  solid	  (1.40	  g,	  6.24	  mmol).	  	  After	  15	  minutes,	  the	  reaction	  
mixture	  was	  warmed	  to	  room	  temperature	  and	  stirred.	  	  However	  starting	  material	  was	  detected	  by	  TLC	  
and	   the	   reaction	   mixture	   was	   cooled	   down.	   	   Na2CO3	   (0.5	   g	   in	   5	   mL	   H2O)	   and	   1,3-­‐benzodioxole-­‐5-­‐
sulfonylchloride	  (0.3	  g)	  were	  added	  to	  the	  reaction	  mixture.	  	  After	  15	  minutes,	  the	  reaction	  mixture	  was	  
warmed	   to	   room	   temperature	   and	   stirred.	   	  No	   starting	   	  material	  was	   detected	   by	   TLC.	   	   The	   reaction	  
mixture	  was	  diluted	  with	  CH2Cl2	  and	  the	  organic	  layer	  extract	  was	  collected.	  	  After	  collecting	  the	  organic	  
layer,	   the	   extract	  was	  dried	  with	  Na2SO4,	   filtered,	   and	  evaporated	  under	   reduced	  pressure.	   	  Using	   an	  
EtOAc-­‐hexanes	   (1:5)	  mixture	  as	   an	  eluent,	   the	   residue	  was	  purified	  by	   flash	   chromatography	  on	   silica	  
gel.	   	   This	   provided	   a	   product	   (2.35	   g,	   87.9%)	   as	   a	  white	   foamy	   solid.	   	   After	   the	  NMR	  was	   taken,	   the	  
residue	  was	  purified	  by	  flash	  chromatography	  on	  silica	  gel.	  	  This	  provided	  a	  pure	  product,	  KY-­‐19	  (2.70	  g,	  
82.0%),	  as	  a	  foamy	  white	  solid.	  	  	  
1H	  NMR	  (400	  MHz,	  CDCl3)	  δ	  7.33	  (dd,	  J	  =	  8.4,	  2.0	  Hz,	  1H),	  7.30-­‐7.28	  (m,	  1H),	  7.27-­‐7.20	  (m,	  3H),	  7.18	  (d,	  J	  
=	  1.6	  Hz,	  1H),	  6.88	  (d,	  J	  =	  8.4	  Hz,	  1H),	  6.09	  (s,	  2H),	  4.59	  (d	  br,	  J	  =	  	  6	  Hz,	  1H),	  3.93	  (s,	  1H),	  3.75	  (s,	  1H),	  3.14-­‐
2.98	  (m,	  3H),	  2.93-­‐2.82	  (m,	  2H),	  1.51-­‐1.37	  (m,	  1H),	  1.34	  (s,	  12H),	  1.31-­‐1.24	  (m,	  2H),	  0.86-­‐0.79	  (m,	  6H);	  13C	  
NMR	   (100	   MHz,	   CDCl3)	   δ	   156.23,	   151.68,	   148.53,	   137.94,	   131.64,	   129.80	   (2C),	   128.72	   (2C),	   126.69,	  
KY-­‐19	  KY-­‐15	  
123.37,	  108.58,	  107.86,	  102.55,	  79.94,	  76.92,	  73.19,	  55.09,	  54.74,	  53.95,	  39.20,	  35.89,	  28.48	  (2C),	  23.28,	  
22.96,	  10.80,	  10.52.	  	  
Synthesis	  of	  tert-­butyl	  (2S,3R)-­4-­(N-­(2-­ethylbutyl)-­4-­nitrophenylsulfonamido)-­3-­hydroxy-­1-­
phenylbutan-­2-­ylcarbamate	  (KY-­21)	  
	  




To	  an	  ice	  cooled	  solution	  of	  the	  above	  secondary	  amine,	  KY-­‐15	  (2.19	  g,	  6	  mmol)	   in	  CH2Cl2	  (50	  mL)	  was	  
added	  to	  an	  aqueous	  solution	  of	  Na2CO3	  (1.59	  g,	  15	  mmol	  in	  20	  mL	  of	  H2O)	  followed	  by	  the	  slow	  addition	  
of	  4-­‐nitrobenzenesulfonylchloride	  solid	  (1.53	  g,	  6.29	  mmol).	  	  After	  15	  minutes,	  the	  reaction	  mixture	  was	  
warmed	  to	  room	  temperature	  and	  stirred.	  	  The	  reaction	  mixture	  was	  diluted	  with	  CH2Cl2	  and	  the	  organic	  
layer	   extract	   was	   collected.	   	   After	   collecting	   the	   organic	   layer,	   the	   extract	   was	   dried	   with	   Na2SO4,	  
filtered,	   and	   evaporated	  under	   reduced	  pressure.	   	   This	   product	  was	   purified	   by	   recrystallization	   from	  










A	   solution	   of	   the	   above	   (R)-­‐(hydroxyethylamino)sulfonamide	   compound,	   KY-­‐19	   (0.5	   g,	   0.91	  mmol),	   in	  
trifluoroacetic	  acid	   (3	  mL)	  and	  CH2Cl2	   (10	  mL)	  was	   stirred	  at	   room	  temperature	   for	  1	  hour.	   	  After	   this	  
period	  the	  reaction	  mixture	  was	  concentrated	  under	  reduced	  pressure	  and	  the	  residue	  was	  dissolved	  in	  
toluene	   (5	   mL)	   and	   the	   solvent	   again	   was	   evaporated	   under	   reduced	   pressure.	   	   The	   residue	   was	  
dissolved	   in	   acetonitrile	   (10	   mL)	   and	   cooled	   to	   0°	   C.	   	   Diisopropylethylamine	   (DIPEA)	   (0.45	   mL,	   2.73	  
mmol)	  and	  THF	  alcohol	  mixed	  carbonate	  (0.26	  g,	  0.91	  mmol)	  were	  added	  to	  the	  solution.	  	  The	  mixture	  
was	   stirred	   at	   room	   temperature	  overnight.	   	  However,	   starting	  material	  was	  detected	   in	   the	   TLC	   and	  
additional	   THF	   alcohol	   mixed	   carbonate	   (	   0.20	   g)	   was	   added	   to	   the	   solution	   and	   was	   stirred	   for	   an	  
additional	  3	  hours.	   	  The	  reaction	  mixture	  was	  diluted	  with	  EtOAc	  (70	  mL)	  and	  was	  washed	  with	  water	  
(15	  mL)	  and	  saturated	  sodium	  chloride	  solution	  (15	  mL).	  	  The	  organic	  portion	  was	  extracted,	  dried	  with	  
Na2SO4,	   filtered,	   and	   concentrated	   under	   reduced	   pressure.	   	   The	   residue	   was	   purified	   by	   flash	  
chromatography	   on	   silica	   gel	   using	   an	   EtOAc-­‐hexanes	   (1:1)	  mixture	   as	   an	   eluent	   to	   provide	   the	   pure	  
product	  (0.50	  g,	  60.2%).	  
1H	  NMR	  (400	  MHz,	  CDCl3)	  δ	  7.34	  (dd,	  J	  =	  8.4,	  2.0	  Hz,	  1H),	  7.30-­‐7.26	  (m,	  2H),	  7.22	  (br	  d,	  J	  =	  7.2	  Hz,	  3H),	  	  
7.17	  (d,	  J	  =	  3	  Hz,	  1H),	  6.90	  (d,	  J	  =	  8.0	  Hz,	  1H),	  6.10	  (s,	  2H),	  5.64	  (d,	  J	  =	  4.8	  Hz,	  1H),	  5.01	  (dd,	  J	  =	  14.4,	  6.4	  
Hz,	  1H),	  4.88	  (d,	  J	  =	  9.2	  Hz,	  1H),	  3.95	  (dd,	  J	  =	  9.6,	  6.4	  Hz,	  1H),	  3.89-­‐3.78	  (m,	  3H),	  3.71-­‐3.65	  (m,	  3H),	  3.14-­‐
KY-­‐23	  KY-­‐19	  
3.07	  (m,	  2H),	  3.05	  (dd,	  J	  =	  14.7,	  9.2	  Hz,	  1H),	  2.94-­‐2.87	  (m,	  1H),	  2.86-­‐2.77	  (m,2H),	  1.48-­‐1.40	  (m,	  3H),	  1.36-­‐





Boc	  Deprotection	  and	  Coupling	  
	  
Procedure:	  
A	   solution	   of	   the	   above	   (R)-­‐(hydroxyethylamino)sulfonamide	   compound,	   KY-­‐17	   (0.5	   g,	   0.94	  mmol),	   in	  
trifluoroacetic	  acid	   (3	  mL)	  and	  CH2Cl2	   (10	  mL)	  was	   stirred	  at	   room	  temperature	   for	  1	  hour.	   	  After	   this	  
period	  the	  reaction	  mixture	  was	  concentrated	  under	  reduced	  pressure	  and	  the	  residue	  was	  dissolved	  in	  
toluene	  (5	  mL).	  	  The	  solvent	  was	  then	  evaporated	  under	  reduced	  pressure.	  	  The	  residue	  was	  dissolved	  in	  
acetonitrile	   (10	  mL)	  and	  cooled	  to	  0°	  C.	   	  Diisopropylethylamine	  (DIPEA)	  (0.47	  mL,	  2.82	  mmol)	  and	  THF	  
alcohol	  mixed	  carbonate	   (0.29	  g,	  0.94	  mmol)	  were	  added	   to	   the	   solution.	   	  The	  mixture	  was	   stirred	  at	  
room	  temperature	  overnight.	  	  No	  starting	  material	  was	  detected	  in	  the	  TLC.	  	  The	  reaction	  mixture	  was	  
diluted	  with	  EtOAc	  (100	  mL)	  and	  was	  washed	  with	  water	  (15	  mL)	  and	  saturated	  sodium	  chloride	  solution	  
(15	  mL).	  	  The	  organic	  portion	  was	  dried	  with	  Na2SO4,	  filtered,	  and	  concentrated	  under	  reduced	  pressure.	  	  
The	  residue	  was	  purified	  by	  flash	  chromatography	  on	  silica	  gel	  using	  an	  EtOAc-­‐hexanes	  (1:1)	  mixture	  as	  
KY-­‐17	   KY-­‐25	  
an	  eluent	  to	  provide	  the	  product	  (0.49	  g).	  	  After	  detecting	  impurities	  in	  the	  NMR,	  the	  residue	  was	  again	  
then	  purified	  by	  flash	  chromatography	  on	  silica	  gel	  using	  an	  EtOAc-­‐hexanes	  (2:5)	  mixture	  as	  an	  eluent.	  
1H	   NMR	   (400	   MHz,	   CDCl3)	   δ	   7.73-­‐7.69	   (m,	   2H),	   7.30-­‐7.21	   (m,	   6H),	   7.01-­‐7.69	   (m,	   2H),	  	  
5.64	  (d,	  J	  =	  5.2	  Hz,	  1H),	  5.01	  (dd,	  J	  =	  6,	  4.4	  Hz,	  1H),	  4.88	  (d,	  J	  =	  9.6,	  1H),	  3.96-­‐3.92	  (m,	  1H),	  3.88-­‐3.79	  (m,	  
2H),	  3.71-­‐3.65	  (m,	  2H),	  3.16-­‐3.03	  (m,	  3H),	  2.98-­‐2.87	  (m,	  2H),	  2.84-­‐2.78	  (m,	  2H),	  1.66-­‐1.58	  (m,	  3H),	  1.48-­‐








A	  solution	  of	   the	  above	   (R)-­‐(hydroxyethylamino)sulfonamide	  compound,	  KY-­‐21	   (0.6	  g,	  1.092	  mmol),	   in	  
trifluoroacetic	  acid	  (3	  mL)	  and	  CH2Cl2	   (10	  mL)	  was	  stirred	  at	  room	  temperature	  for	  2	  hours.	   	  After	  this	  
period	  the	  reaction	  mixture	  was	  concentrated	  under	  reduced	  pressure	  and	  the	  residue	  was	  dissolved	  in	  
toluene	   (5	   mL)	   and	   the	   solvent	   again	   was	   evaporated	   under	   reduced	   pressure.	   	   The	   residue	   was	  
dissolved	   in	   acetonitrile	   (10	  mL)	   and	   cooled	   to	   0°	   C.	   	  Diisopropylethylamine	   (DIPEA)	   (0.529	  mL,	   3.276	  
mmol)	   and	   THF	   alcohol	   mixed	   carbonate	   (0.323	   g,	   1.092	   mmol)	   were	   added	   to	   the	   solution.	   	   The	  
resulting	  mixture	  was	  stirred	  at	  room	  temperature	  overnight.	  	  However,	  starting	  material	  was	  detected	  
KY-­‐27	  KY-­‐21	  
in	   the	   TLC	   and	   C13H13NO7	   (0.25	   g)	   and	   DIPEA	   (0.2	   mL)	   were	   added	   to	   the	   solution	   and	   was	   stirred	  
overnight.	  	  The	  reaction	  mixture	  was	  diluted	  with	  EtOAc	  (100	  mL)	  and	  was	  washed	  with	  water	  (15	  mL)	  
and	   saturated	   sodium	  chloride	   solution	   (15	  mL).	   	   The	  organic	  portion	  was	  dried	  with	  Na2SO4,	   filtered,	  
and	  concentrated	  under	  reduced	  pressure.	  	  The	  residue	  was	  purified	  by	  flash	  chromatography	  on	  silica	  
gel	  using	  an	  EtOAc-­‐hexanes	  (1:1)	  mixture	  as	  an	  eluent	  to	  provide	  the	  pure	  product	  (0.55	  g,	  83.0%)	  as	  a	  








A	  mixture	   of	   the	   nitro	   compound,	   KY-­‐27	   (0.55	   g,	   0.45	  mmol),	   and	   SnCl2·∙2H2O	   (1.86	   g,	   8.25	  mmol)	   in	  
EtOAc	   (20	  mL)	   was	   heated	   at	   80°C	   for	   3	   hours.	   	   The	   reaction	  mixture	   was	   allowed	   to	   cool	   to	   room	  
temperature	   and	  was	   treated	  with	   saturated	   aqueous	   NaHCO3	   solution	   (15	  mL).	   	   It	   was	   diluted	  with	  
EtOAc	   (100	  mL)	   and	   the	   organic	   layer	   was	   collected.	   	   The	   aqueous	   layer	   was	   further	   extracted	   with	  
EtOAc	  (100	  mL,	  2	  x).	  	  The	  combined	  organic	  extract	  was	  washed	  with	  saturated	  NaCl	  solution,	  dried	  with	  
Na2SO4,	  filtered,	  and	  evaporated	  to	  yield	  a	  yellowish	  solid.	  	  Flash	  chromatography	  on	  silica	  gel,	  using	  	  an	  
EtOAc-­‐hexanes	  (1:1)	  mixture	  as	  an	  eluent	  provided	  the	  product	  (0.280	  g,	  29.5%)	  as	  a	  white	  solid.	  
KY-­‐29	  KY-­‐27	  
1H	  NMR	  (400	  MHz,	  CDCl3)	  δ	  7.56-­‐7.53	  (m,	  2H),	  7.38-­‐7.24	  (m,	  2H),	  7.25-­‐7.19	  (m,3H),	  6.71-­‐6.67	  (m,	  2H),	  
5.64	  (d,	  J	  =	  5.2	  Hz,	  1H),	  5.00	  (dd,	  J	  =	  14.4,	  6.0	  Hz,	  1H),	  4.88	  (d,	  J	  =	  9.2	  Hz,	  1H),	  4.16	  (s,	  2H),	  3.96-­‐3.92	  (m,	  
1H),	  3.89-­‐3.80	  (m,3H),	  3.71-­‐3.65	  (m,	  2H),	  3.15-­‐3.02	  (m,	  3H),	  2.95-­‐2.87	  (m,	  2H),	  2.83-­‐2.77	  (m,	  2H),	  1.64-­‐
1.57	  (m,	  1H),	  1.58-­‐1.40	  (m,	  3H),	  1.33-­‐1.25	  (m,	  4H),	  0.84-­‐0.80	  (m,	  6H).	  
HIV-­1	  Protease	  Inhibition	  Assays	  
	  
	   The	   HIV-­‐1	   protease	   inhibitors	   activities	   were	   determined	   by	   fluorescence	   resonance	   energy	  
transfer	  (FRET)	  method.	   	  The	  protease	  substrate	  used	  was	  Arg-­‐Glu(EDANS)-­‐Ser-­‐Gln-­‐Asn-­‐Tyr-­‐Pro-­‐Ile-­‐Val-­‐
Gln-­‐Lys(DABCYL)-­‐Arg,	   which	   was	   purchased	   from	   Molecular	   Probes.	   	   The	   energy	   donor	   (EDANS	   and	  
acceptor	   (DABCYL)	  dyes	  were	   labeled	  at	  both	  ends	  of	   the	  peptide.	   	  Fluorescence	  measurements	  were	  
carried	   out	   on	   a	   fluorescence	   spectrophotometer	   (Photon	   Technology	   International)	   at	   30°	   C	   and	  
excitation	  and	  emission	  wavelengths	  were	  set	  at	  340	  and	  490	  nm.	   	  Each	  reaction	  was	  recorded	  for	  10	  
minutes.	  	  	  
	   Wild-­‐type	  HIV-­‐1	  protease	   (Q7K)	  was	  desalted	  through	  PD-­‐19	  columns	   (Amersham	  Biosciences)	  
and	  sodium	  acetate	  (20	  mM,	  pH	  5)	  were	  used	  as	  an	  elution	  buffer.	   	  The	  protease	  concentrations	  were	  
around	  50	  nM	  estimated	  by	  UV	  spectrophotometry	  at	  280	  nm.	  	  The	  protease	  inhibitors	  were	  dissolved	  
in	  dimethylsulfoxide)	  DMSO	  and	  diluted	  to	  appropriate	  concentrations.	  	  Protease	  (2	  µL)	  and	  inhibitor	  (2	  
µL)	  or	  DMSO	  were	  mixed	  and	  incubated	  for	  20-­‐30	  minutes	  at	  room	  temperature	  before	  initializing	  the	  
substrate	  cleavage	  action.	   	   In	  all	  experiments,	  150	  µL	  of	  1	  µM	  substrate	  were	  used	  in	  substrate	  buffer	  
[0.1	   M	   sodium	   acetate,	   1	   M	   sodium	   chloride,	   1	   mM	   ethylenediaminetetraacetic	   acid	   (EDTA),	   1	   mM	  
dithiothreitol	   (DTT),	   2%	   DMSO	   and	   1	   mg/mL	   bovine	   serum	   albumin	   (BSA)	   with	   an	   adjusted	   pH	   4.7].	  	  
Inhibitor	  binding	  constant	   (Ki)	  values	  were	  obtained	  by	  nonlinear	  regression	  fitting	   (GraFit	  5,	  Erithacus	  
software)	   to	   plot	   the	   initial	   velocity	   as	   a	   function	   of	   inhibitor	   concentrations	   based	   on	   the	  Morrison	  
equation.	  	  The	  initial	  velocities	  were	  derived	  from	  the	  linear	  range	  of	  reaction	  curves.	  	  	  
Results	  
	   The	   substrate	   envelope	   hypothesis	   has	   suggested	   the	  mechanism	   of	   darunavir’s	   potency	   and	  
effectiveness	  against	  drug	  resistant	  HIV-­‐1.	   	  By	  basing	  future	  protease	  inhibitor	  design	  on	  the	  substrate	  
envelope,	   the	   inhibitor	   can	   have	   tighter	   binding	   with	   the	   protease.	   	   Along	   with	   the	   tighter	   binding,	  
mutations	  that	  decrease	  inhibitor	  binding	  would	  also	  decrease	  substrate	  affinity.	  	  The	  compounds	  KY-­‐23,	  
KY-­‐25,	  and	  KY-­‐29	  were	  analogs	  of	  darunavir	  and	  synthesized	  with	  the	  addition	  of	  2-­‐ethylbutyl	  group	  and	  
various	   sulfonyl	   chloride	   groups.	   	   In	   order	   to	   determine	   the	   inhibitor	   binding	   to	   the	   protease,	   a	  
fluorescence	   resonance	   energy	   transfer	   (FRET)	   assay	   was	   performed	   by	   using	   various	   inhibitor	  
concentrations.	   	  The	  initial	  velocities	  were	  measured	  and	  used	  with	  the	  Morrison	  equation	  in	  order	  to	  
calculate	  the	  Ki	  values.	  	  	  	  	  	  	  	  
The	   compounds,	   KY-­‐23,	   KY-­‐25,	   and	   KY-­‐29,	   were	   selected	   based	   on	   computational	   analysis	   of	  
prospective	  compounds	   that	  would	   fit	  within	   the	  substrate	  envelope.	   	  The	  general	  mechanism	  can	  be	  
seen	   in	   Figure	   15.	   	   The	   initial	   step	   required	   the	  opening	  of	   the	   epoxide	   ring	  with	   the	  primary	   amine,	  
forming	  an	  amino	  alcohol	  with	   the	  2-­‐ethylbutyl	   ligand.	   	   The	   second	   step	   required	   the	   reaction	  of	   the	  
amino	   alcohol	  with	   various	   sulfonyl	   chloride	   groups,	   yielding	   a	   sulfonamide	  with	   selected	   substituent	  
groups.	  	  The	  third	  step	  required	  deprotection	  of	  the	  Boc	  group	  and	  the	  addition	  of	  bis-­‐THF.	  	  Bis-­‐THF	  has	  
been	   shown	   to	  be	  effective	   for	   interaction	   in	   the	  P2’	   pocket	  during	   the	   initial	   discovery	  of	   darunavir.	  	  
The	  addition	  of	  the	  bis-­‐THF,	  yielded	  the	  final	  compounds	  KY-­‐23,	  KY-­‐25,	  and	  KY-­‐29.	  	  	  
The	   HIV-­‐1	   protease	   inhibitors	   activities	   were	   determined	   by	   fluorescence	   resonance	   energy	  
transfer	   (FRET)	   method.	   	   The	   inhibitor	   binding	   constant	   (Ki)	   values	   were	   obtained	   by	   nonlinear	  
regression	   fitting	   (GraFit	   5,	   Erithacus	   software)	   in	   order	   to	   plot	   the	   initial	   velocity	   as	   a	   function	   of	  
inhibitor	  concentrations	  based	  on	  the	  Morrison	  equation.	   	  The	   initial	  velocities	  were	  derived	  from	  the	  
linear	   range	  of	   reaction	   curves.	   	  When	   compared	   to	   a	  Dixon	   and	   Lineweaver-­‐Burk	   plot,	   the	  Morrison	  
equation	  provided	  extreme	  precision	  and	  accuracy	  for	  the	  Ki	  values.	  
A	  donating	  group	  (EDANS)	  and	  accepting	  group	  (DABCYL)	  is	  attached	  was	  attached	  to	  a	  natural	  
substrate	   of	  HIV	   protease.	   	   Prior	   to	   protease	   cleavage,	  DABCYL	  would	   quench	   EDANS,	   resulting	   in	   no	  
detection	  of	  fluorescence	  form	  EDANS.	  	  After	  the	  cleavage	  of	  the	  substrate	  from	  protease,	  EDANS	  was	  
no	   longer	   quenched	   by	   DABCYL,	   allowing	   EDANS	   to	   fluoresce.	   	   The	   activity	   of	   the	   protease	   can	   be	  
monitored	  by	  analyzing	  the	  change	  of	  EDANS	  fluorescence	  intensity.	  	  	  
In	  Figure	  16,	  Figure	  17,	  Figure	  18,	  and	  Figure	  19,	  the	  x	  axis	  represented	  time	  in	  seconds	  and	  the	  
y	   axis	   represented	   fluorescence	   intensity.	   	   The	   legend	   showed	   increasing	   concentrations	   of	   protease	  
inhibitor	  and	  controls	  of	  DMSO,	  which	  had	  no	  protease	  inhibitor	  present.	  	  The	  initial	  velocity	  was	  taken	  
and	  was	  analyzed	  with	  the	  Morrison	  equation	  seen	   in	  Figure	  20.	   	  As	  seen	   in	  all	   the	  figures,	  the	  DMSO	  
sample	  had	  the	  highest	  slope	  and	  the	  slopes	  were	  gradually	  lower	  more	  inhibitor	  was	  introduced.	  	  The	  
lowest	   slopes	   seen	   in	   Figure	  16	   (wild-­‐type),	   Figure	  17	   (M1),	   Figure	  18	   (M3),	   and	  Figure	  19	   (M4)	  were	  
inhibitor	   concentrations	   3.8	   µM,	   4.5	   µM,	   3.5	   µM,	   and	   3.2	   µM,	   respectively.	   	   As	   seen	   with	   all	   the	  
compounds,	   the	   increase	   of	   inhibitor	   concentration	   resulted	   in	   a	   lower	   slope,	   suggesting	   decreased	  
protease	   activity.	   	   While	   only	   the	   results	   from	   KY-­‐29	   were	   shown,	   FRET	   assays	   were	   done	   for	   all	  
compounds.	  	  
	   The	   calculated	   Ki	   values	   were	   tabulated	   into	   Table	   1	   and	   listed	   the	   Ki	   values	   in	   nM	   for	  
compounds	  KY-­‐23,	  KY-­‐25,	  and	  KY-­‐29	  with	  the	  wild-­‐type	  and	  mutant	  multidrug	  resistant	  HIV	  proteases,	  
including	  the	  darunavir	  resistant	  mutant,	  I50V/A71V.	  	  The	  new	  darunavir	  analogs	  synthesized	  contained	  
a	  2-­‐ethylbutyl	  ligand,	  unlike	  darunavir	  with	  had	  and	  ethyl	  ligand.	  	  When	  comparing	  KY-­‐29	  and	  darunavir,	  
the	  structures	  contain	  the	  same	  primary	  amine	  and	  differ	  with	  the	   ligand.	   	  The	  simple	  addition	  of	  this	  
ligand	  increased	  inhibitor	  binding	  affinity	  for	  most	  compounds,	  except	  the	  M1	  and	  wild-­‐type	  protease.	  	  
When	  comparing	  the	  substituent	  groups	  of	  KY-­‐23	  and	  KY-­‐25	  with	  the	  other	  compounds,	  both	  KY-­‐23	  and	  
KY-­‐25	   contained	   bulky	   polar	   groups.	   	   However,	   KY-­‐25	   contained	   a	   4-­‐OCH3	   group	  which	   is	   allowed	   to	  
rotate	   freely	   unlike	  KY-­‐23.	   	   The	  4-­‐OCH3	   substituent	  was	   extremely	   effective	   against	   the	  M1	  and	  wild-­‐
type	   proteases.	   	   Although	   KY-­‐23	  was	   not	   as	   effective	  with	   the	  M1	   and	  wild-­‐type	   protease,	   the	   polar	  
cyclic	  structure	  of	  KY-­‐23	  was	  more	  potent	  against	  the	  M4	  protease	  than	  any	  other	  compound.	  	  	  	  	  	  	  	  
The	   inhibitors	   synthesized	   showed	   increased	   activity	   against	   both	   the	   wild-­‐type	   and	   mutant	  
proteases	   when	   compared	   to	   darunavir.	   	   When	   comparing	   the	   compounds	   with	   darunavir,	   these	  
compounds	  showed	  a	  significant	  increase	  in	  inhibitor	  binding	  affinity	  for	  at	  least	  one	  of	  the	  mutants	  and	  
the	  wild-­‐type	  protease.	  	  The	  results	  indicated	  that	  the	  addition	  of	  the	  2-­‐ethylbutyl	  ligand	  and	  substituent	  
group	  increased	  inhibitor	  binding	  and	  suggests	  that	  these	  analogs	  fit	  better	  into	  the	  substrate	  envelope	  
than	  darunavir.	  	  
	  Discussion	  
	   The	  darunavir	  analogs,	  KY-­‐23,	  KY-­‐25,	  and	  KY-­‐29,	  incorporated	  the	  2-­‐ethylbutyl	  ligand	  and	  various	  
substituent	  groups	  in	  order	  to	  improve	  the	  fit	  within	  P1	  pocket.	  	  By	  developing	  drugs	  with	  the	  substrate	  
envelope	  hypothesis,	  mutations	  that	  decrease	   inhibitor	  binding	  would	  also	  decrease	  substrate	  affinity.	  	  
In	   order	   to	   test	   the	   potency	   of	   these	   analogs,	   a	   FRET	   assay	   was	   performed.	   	   By	   monitoring	   the	  
fluorescence	   of	   EDANS	   over	   time,	   the	   protease	   activity	   could	   be	   monitored.	   	   The	   initial	   velocity	   of	  
fluorescence	   over	   time	   graph	  was	  measured	   and	   the	  Morrison	   equation	  was	   used	   to	   calculate	   the	   Ki	  
values.	  	  	  	  	  	  	  	  
	  	   When	  comparing	  darunavir	  and	  synthesized	  compounds	  with	  the	  wild-­‐type	  protease,	  both	  KY-­‐
23	  and	  KY-­‐25	  had	  a	  10	  fold	   increase	  for	   inhibitor	  binding	  affinity.	   	  As	  seen	  in	  KY-­‐29	  and	  darunavir,	  the	  
addition	  of	   the	  2-­‐ethylbutyl	  did	  not	  change	   the	  Ki	  value	  with	   the	  wild-­‐type	  protease.	   	  Although	   the	  2-­‐
ethylbutyl	   ligand	   did	   not	   affect	   the	   Ki	   value,	   this	   suggested	   that	   the	   change	   in	   the	   substituent	   group	  
might	   increase	   the	  binding	   affinity	  of	   these	  protease	   inhibitors.	   	   Since	  KY-­‐23	   and	  KY-­‐25	   contain	  bulky	  
polar	   substituent	   groups,	   the	   results	   suggested	   that	   these	   groups	   might	   provide	   a	   better	   fit	   in	   the	  
substrate	  envelope.	  
	   KY-­‐25	   had	   a	   10	   fold	   tighter	   inhibitor	   binding	   affinity	   than	   darunavir	   when	   comparing	   the	  
compounds	   and	   darunavir	   with	   the	   M1	   mutant.	   	   After	   looking	   at	   the	   crystal	   structure,	   the	   V82A	  
mutation	  would	  most	  likely	  affect	  the	  binding	  of	  the	  2-­‐ethylbutyl	  ligand	  and	  the	  substituent	  group.	  	  The	  
valine	   to	   alanine	  mutation	  would	   change	   the	   isopropyl	   group	   into	   a	  methyl	   group.	   	   This	   change	   to	   a	  
smaller	  amino	  acid	  structure	  might	  negatively	  affect	  binding	  with	  these	   inhibitors.	   	  As	  seen	  in	  Table	  1,	  
darunavir	  had	  the	  tighter	   inhibitor	  binding	  affinity	  than	  KY-­‐29.	   	  Since	  the	  ethyl	  group	   in	  darunavir	  was	  
less	   bulky	   than	   the	   2-­‐ethylbutyl	   group,	   the	   2-­‐ethybutyl	   ligand	  was	   too	   big	   and	  protruded	  outside	   the	  
substrate	  envelope.	  	  However,	  KY-­‐25	  contains	  both	  the	  2-­‐ethylbutyl	  ligand	  and	  a	  4-­‐OCH3	  group.	  	  Since	  4-­‐
OCH3	   is	   a	   polar	   bulky	   group	   and	   can	   rotate	   freely,	   there	   might	   be	   stronger	   hydrogen	   bonding	  
interactions	   with	   the	   alanine	   change.	   	   The	   interaction	   of	   4-­‐OCH3	   and	   alanine	   might	   cause	   a	  
conformational	  change,	  allowing	  the	  2-­‐ethylbutyl	   ligand	  to	  bind	  tightly	  into	  the	  active	  site.	   	  Due	  to	  the	  
few	  hydrogens	  and	  the	  cyclic	  nature	  of	  	  KY-­‐29,	  the	  inability	  to	  rotate	  might	  affect	  the	  hydrogen	  bonding	  
with	  the	  alanine.	  	  	  
When	   comparing	   the	   compounds	   and	   darunavir	   with	   the	  M3	  mutant,	   KY-­‐29	   had	   the	   tightest	  
inhibitor	  binding	  affinity	  and	  had	  a	  slight	  lower	  Ki	  value	  than	  darunavir	  by	  0.002	  nM.	  	  After	  looking	  at	  the	  
crystal	  structure,	  the	  I84V	  mutation	  would	  most	  likely	  affect	  binding	  of	  the	  2-­‐ethylbutyl	   ligand	  and	  the	  
substituent	  group.	   	  This	  mutation	  changed	  an	  isoleucine	  to	  valine,	  substituting	  a	  bulky	  sec-­‐butyl	  group	  
with	  a	  smaller	   isopropyl	  group.	   	  The	  addition	  of	  the	  2-­‐ethylbutyl	   ligand	   increased	  the	   inhibitor	  binding	  
affinity	  when	  comparing	  KY-­‐29	  and	  darunavir.	  	  Due	  to	  the	  larger	  size	  and	  bulk	  of	  the	  2-­‐ethylbutyl	  group,	  
this	  ligand	  might	  be	  able	  interact	  with	  the	  smaller	  valine.	  	  Unlike	  the	  wild-­‐type	  protease,	  both	  KY-­‐23	  and	  
KY-­‐25	   had	   higher	   Ki	   values,	   suggesting	   a	   lower	   inhibitor	   binding	   affinity.	   	   The	   polar	   bulky	   substituent	  
groups	  of	  KY-­‐23	  and	  KY-­‐25	  might	  protrude	  out	  of	   the	  substrate	  envelope,	  affecting	   the	  binding	  of	   the	  
inhibitor.	  	  When	  comparing	  these	  polar	  bulky	  groups	  with	  the	  4-­‐NH2	  groups	  in	  KY-­‐29	  and	  darunavir,	  the	  
smaller	  nonpolar	  primary	  amines	  might	  better	  interact	  with	  the	  valine	  residues.	  	  	  
The	  M4	  mutant	  protease	   is	  the	  classic	  drug	  resistant	  variant	  of	  darunavir.	   	  KY-­‐23	  had	  a	  tighter	  
inhibitor	  binding	  affinity	   than	  darunavir	  by	  a	  100	   fold	  when	  comparing	   the	  compounds	  and	  darunavir	  
with	  the	  M4	  mutant.	  	  After	  looking	  at	  the	  crystal	  structure,	  the	  I50V	  mutation	  would	  most	  likely	  affect	  
binding	  of	  the	  2-­‐ethylbutyl	  ligand	  and	  the	  substituent	  group.	  	  This	  mutation	  substituted	  an	  isoleucine	  for	  
a	  valine,	  changing	  the	  bulky	  sec-­‐butyl	  group	  to	  smaller	  isopropyl	  group.	  	  The	  addition	  of	  the	  2-­‐ethylbutyl	  
ligand	  significantly	  increased	  the	  inhibitor	  binding	  affinity	  when	  comparing	  KY-­‐29	  and	  darunavir.	   	  Since	  
the	  2-­‐ethylbutyl	   ligand	   is	  much	   larger	   than	   the	  ethyl	   ligand,	   the	   larger	   group	   can	   compensate	   for	   the	  
change	   in	   valine.	   	   However,	   the	   smaller	   4-­‐NH2	   group	  might	   not	   be	   large	   enough	   to	   interact	  with	   the	  
valine.	   However	   KY-­‐23	   might	   interact	   better	   than	   KY-­‐25	   because	   KY-­‐23	   contains	   a	   cyclic	   bulky	   polar	  
group.	  	  The	  cyclic	  shape	  of	  the	  substituent	  group	  might	  prevent	  the	  cyclic	  group	  from	  rotating	  while	  the	  
4-­‐OCH3	   group	   is	   free	   to	   rotate.	   	   The	   rotation	   seen	   in	   the	   4-­‐OCH3	   group	   might	   cause	   some	   steric	  
hindrance	  with	  the	  valine.	  	  	  
The	   method	   of	   determining	   these	   compounds	   employed	   a	   new	   general	   strategy	   for	   drug	  
discovery.	  	  Rather	  than	  randomly	  testing	  various	  darunavir	  analogs,	  the	  substrate	  envelope	  allowed	  for	  
structured-­‐based	  design.	  	  When	  comparing	  the	  compounds	  with	  darunavir,	  these	  compounds	  showed	  a	  
significant	   increase	   in	   inhibitor	   binding	   affinity	   for	   at	   least	   one	   of	   the	   mutants	   and	   the	   wild-­‐type	  
protease.	  	  Due	  to	  the	  increased	  potency	  of	  these	  drugs,	  these	  compounds	  are	  currently	  being	  tested	  on	  
animals	   for	   pharmacokinetics	   and	   pharmacodynamics	   studies.	   	   Although	   these	   compounds	   were	  
showed	  an	  increased	  binding	  affinity	  compared	  with	  darunavir,	  there	  was	  still	  some	  drug	  resistance	  with	  
the	   mutant	   proteases.	   	   Future	   studies	   can	   focus	   on	   further	   analyzing	   crystal	   structures	   to	   locate	  
positions	  which	  protrude	  from	  the	  substrate	  envelope	  and	  new	  analogs	  can	  be	  synthesized	  to	  improve	  
these	   problems.	   	   	   Although	   none	   of	   the	   compounds	   outperformed	   darunavir	   for	   all	   the	   protease	  
mutants,	  a	  combination	  of	  these	  compounds	  might	  be	  useful	  for	  HAART	  therapy.	  
A	  major	  problem	  with	  HAART	  is	  that	  it	  requires	  many	  pills	  for	  treatment	  of	  HIV.	  	  By	  developing	  
more	  potent	  drugs,	  less	  medication	  is	  required	  to	  achieve	  the	  same	  effect.	  	  Introducing	  less	  amount	  of	  
drug	   into	   the	   body	  might	   also	   solve	   some	   of	   the	   toxicity	   problems	   encountered	  with	  HAART	   as	  well.	  	  
Along	  with	   the	   toxicity	   and	   potency,	   the	   high	   yielding	   synthesis	   for	   these	   analogs	  might	   prove	   to	   be	  
more	  economical	  to	  the	  pharmaceutical	  companies.	  
These	  compounds	  were	  significantly	  more	  potent	  against	  the	  wild-­‐type	  and	  MDR	  HIV-­‐1	  protease	  
variants	  than	  any	  protease	  inhibitor.	  	  By	  designing	  drugs	  based	  off	  of	  the	  substrate	  envelope	  hypothesis,	  
mutations	  that	  alter	  inhibitor	  binding	  would	  also	  affect	  substrate	  binding	  as	  well.	  	  Further	  development	  
of	  these	  protease	  inhibitors	  may	  lead	  to	  more	  effective	  treatments	  against	  drug-­‐resistant	  HIV-­‐1.	  	  	  While	  
this	  study	  specifically	  looked	  at	  the	  designing	  drugs	  against	  the	  HIV-­‐1	  protease,	  the	  substrate	  envelope	  
can	  be	  used	  to	  design	  drugs	  against	  other	  drug	  targets	  and	  other	  diseases.	  	  	  















Figures	  and	  Tables	  
	  
Figure	  1:	  The	  HIV	  Viron	  
Above	  is	  the	  HIV-­‐1	  viral	  envelope	  structure	  of	  both	  the	  viral	  envelope	  and	  inner	  core(1).	  
	  
	  Figure	  2:	  The	  HIV-­‐1	  lifecycle	  
This	  figure	  shows	  a	  simple	  scheme	  of	  the	  HIV-­‐1	  life	  cycle	  and	  shows	  the	  following	  interactions:	  the	  envelope	  proteins	  of	  the	  
virus	  and	  the	  CD4	  receptor	  and	  coreceptors	  of	  the	  host	  cell	  which	  bind	  the	  viral	  envelope	  to	  the	  host	  membrane.	  	  The	  viral	  
DNA	  is	  then	  enters	  the	  nucleus	  and	  integrates	  with	  the	  host	  chromosomal	  DNA	  and	  is	  catalyzed	  by	  the	  viral	  enzyme	  
integrase.	  	  Expression	  of	  the	  genes	  leads	  to	  production	  of	  viral	  proteins	  and	  RNA.	  	  	  	  The	  HIV	  protease	  then	  cleaves	  the	  gag	  
and	  gag-­‐pol	  proteins	  into	  mature	  components.	  	  Viral	  proteins	  and	  RNA	  are	  assembled	  at	  the	  cell	  surface	  into	  new	  viral	  
particles	  and	  leave	  the	  cell	  through	  budding.	  	  While	  budding,	  the	  viral	  acquires	  an	  outer	  layer	  and	  an	  envelope(7).	  
	  	  
Figure	  3:	  Hydrogen	  bonding	  between	  the	  aspartates	  and	  gem-­‐diol	  of	  the	  tetrahedral	  intermediate	  at	  the	  catalytic	  center	  
(13).	  
	  	  
Figure	  4:	  Schematic	  diagram	  of	  the	  reaction	  mechanism	  based	  on	  the	  non-­‐covalent	  tetrahedral	  intermediate	  
	  	  
Figure	  5:	  Ribbon	  diagram	  of	  the	  crystal	  structure	  of	  the	  HIV-­‐1	  Protease	  
A	  ribbon	  diagram	  of	  crystal	  structure	  of	  a	  substrate	  complex	  of	  the	  homo-­‐dimer	  HIV-­‐1	  protease.	  	  The	  substrate	  is	  shown	  in	  
green;	  the	  catalytic	  aspartic	  acids	  are	  shown	  in	  yellow;	  and	  each	  monomer	  is	  shown	  in	  cyan	  and	  pink(8).	  
	  	  
	  
Figure	  6:	  	  The	  substrate	  envelope	  (A)	  and	  the	  inhibitor	  envelope	  (B)	  (16)	  
The	  substrate	  envelope	  is	  the	  conserved	  area	  of	  the	  natural	  substrates	  of	  HIV	  protease,	  while	  the	  inhibitor	  envelope	  is	  the	  
conserved	  area	  of	  all	  the	  current	  HIV	  protease	  inhibitors.	  
	  
	  	  
Figure	  7:	  	  Superposition	  of	  the	  substrate	  envelope	  and	  the	  inhibitor	  envelope(16)	  
The	  superposition	  of	  the	  substrate	  envelope	  (blue)	  and	  inhibitor	  envelope	  (red).	  	  Areas	  that	  the	  inhibitor	  envelope	  protrudes	  
the	  substrate	  envelope	  confer	  drug	  resistance	  when	  they	  are	  labeled.	  
	  	  
Figure	  8:	  	  Superposition	  of	  the	  substrate	  envelope	  (blue)	  with	  darunavir	  (red);	  the	  places	  where	  darunavir	  protrudes	  out	  
from	  the	  substrate	  envelope	  encounter	  viral	  resistance(22).	  
	  	  
Figure	  9:	  The	  wild-­‐type	  HIV	  protease	  (3EM6)	  with	  darunavir	  binding	  in	  the	  active	  site	  
	  	  
Figure	  10:	  The	  common	  M1	  mutations	  in	  HIV	  protease	  (3EM6)	  with	  darunavir	  binding	  in	  the	  active	  site.	  	  As	  seen	  the	  V82A	  
mutation	  can	  interefere	  with	  darunavir	  binding	  to	  the	  site.	  
	  .
	  
Figure	  11:	  The	  common	  M3	  mutations	  in	  HIV	  protease	  (3EM6)	  with	  darunavir	  binding	  in	  the	  active	  site.	  	  As	  seen	  the	  I84V	  
mutation	  can	  interfere	  with	  darunavir	  binding	  to	  the	  site.	  
	  	  
Figure	  12:	  The	  common	  M4	  mutations	  in	  HIV	  protease	  (3EM6)	  with	  darunavir	  binding	  in	  the	  active	  site.	  	  As	  seen	  the	  I50V	  
mutation	  can	  interfere	  with	  darunavir	  binding	  to	  the	  site.	  
	  	  
Figure	  13:	  Structures	  of	  fluorogenic	  substrates	  DABCYL	  and	  EDANS	  (14)	  
	  Figure	  14:	  Overview	  of	  the	  FRET	  assay	  
A	  donating	  group	  (EDANS)	  and	  accepting	  group	  (DABCYL)	  is	  attached	  to	  a	  natural	  substrate	  of	  HIV	  protease.	  	  When	  the	  
substrate	  is	  uncleaved,	  DABCYL	  quenches	  EDANS	  and	  there	  is	  no	  detection	  of	  fluorescence.	  	  After	  HIV-­‐1	  protease	  cleaves	  the	  
substrate,	  EDANS	  is	  not	  longer	  being	  quenched	  by	  DABCYL	  and	  EDANS	  fluorescence	  can	  be	  detected.	  	  The	  effectiveness	  of	  
the	  protease	  inhibitor	  can	  be	  monitored	  by	  the	  change	  of	  EDANS	  fluorescence	  intensity.	  	  	  	  
	  Figure	  15:	  General	  reaction	  for	  the	  HIV	  protease	  inhibitors	  
	  
	  	  
Figure	  16:	  KY-­‐29	  Fluorescence	  Resonance	  Energy	  Transfer	  for	  HIV	  Protease	  (Q7K)	  
The	  x	  axis	  represented	  time	  in	  seconds	  and	  the	  y	  axis	  represented	  fluorescence	  intensity.	  	  The	  legend	  showed	  increasing	  
concentrations	  of	  protease	  inhibitor	  and	  a	  control	  of	  DMSO,	  which	  had	  no	  protease	  inhibitor	  present.	  	  The	  initial	  velocity	  
was	  taken	  and	  was	  analyzed	  with	  the	  Morrison	  equation.	  	  As	  the	  inhibitor	  concentration	  increased	  the	  lower	  fluorescent	  the	  

































Figure	  17:	  KY-­‐29	  Fluorescence	  Resonance	  Energy	  Transfer	  for	  HIV	  Protease	  (L10I,	  G48V,	  154V,	  L63P,	  V82A)	  
Figure	  17	  showed	  the	  results	  of	  the	  FRET	  assay	  with	  the	  mutant	  HIV	  protease	  (L10I,	  G48V,	  I54V,	  L63P,	  V82A)	  against	  inhibitor	  
KY-­‐29.	  	  The	  x	  axis	  represented	  time	  in	  seconds	  and	  the	  y	  axis	  represented	  fluorescence	  intensity.	  	  The	  legend	  showed	  
increasing	  concentrations	  of	  protease	  inhibitor	  and	  two	  controls	  of	  DMSO,	  which	  had	  no	  protease	  inhibitor	  present.	  	  The	  
initial	  velocity	  was	  taken	  and	  was	  analyzed	  with	  the	  Morrison	  equation.	  	  As	  the	  inhibitor	  concentration	  increased	  the	  lower	  



































Figure	  18:	  KY-­‐29	  Fluorescence	  Resonance	  Energy	  Transfer	  for	  HIV	  Protease	  (L10I,	  L63P,	  A71V,	  G73S,	  I84V,	  L90M)	  
	  
Figure	  18	  showed	  the	  results	  of	  the	  FRET	  assay	  with	  the	  mutant	  HIV	  protease	  (L10I,	  L63P,	  A71V,	  G73S,	  I84V,	  L90M)	  against	  
inhibitor	  KY-­‐29.	  	  The	  x	  axis	  represented	  time	  in	  seconds	  and	  the	  y	  axis	  represented	  fluorescence	  intensity.	  	  The	  legend	  
showed	  increasing	  concentrations	  of	  protease	  inhibitor	  and	  two	  controls	  of	  DMSO,	  which	  had	  no	  protease	  inhibitor	  present.	  	  
The	  initial	  velocity	  was	  taken	  and	  was	  analyzed	  with	  the	  Morrison	  equation.	  	  As	  the	  inhibitor	  concentration	  increased	  the	  

































Figure	  19:	  KY-­‐29	  Fluorescence	  Resonance	  Energy	  Transfer	  for	  HIV	  Protease	  (I50V,	  A71V)	  
Figure	  19	  showed	  the	  results	  of	  the	  FRET	  assay	  with	  the	  mutant	  HIV	  protease	  (L10I,	  L63P,	  A71V,	  G73S,	  I84V,	  L90M)	  against	  
inhibitor	  KY-­‐29.	  	  The	  x	  axis	  represented	  time	  in	  seconds	  and	  the	  y	  axis	  represented	  fluorescence	  intensity.	  	  The	  legend	  
showed	  increasing	  concentrations	  of	  protease	  inhibitor	  and	  two	  controls	  of	  DMSO,	  which	  had	  no	  protease	  inhibitor	  present.	  	  
The	  initial	  velocity	  was	  taken	  and	  was	  analyzed	  with	  the	  Morrison	  equation.	  	  As	  the	  inhibitor	  concentration	  increased	  the	  
































Figure	  20:	  The	  Morrison	  Equation	  was	  used	  to	  determine	  the	  Ki	  values.	  
Km=	  103	  µM	  Kcat	  =	  4.9	  s
-­‐1	  
	  
The	  initial	  velocities	  were	  measured	  from	  these	  graphs	  and	  the	  Morrison	  equation	  was	  used	  to	  calculate	  the	  inhibitor	  
binding	  affinity	  or	  Ki	  values	  seen	  in	  Figure	  20.	  	  Ki	  is	  the	  binding	  affinity;	  [I]	  is	  the	  protease	  inhibitor	  concentration;	  [E]	  is	  the	  
protease	  enzyme	  concentration;	  [S]	  is	  the	  substrate	  concentration;	  f	  is	  one	  of	  the	  fitting	  parameters;	  Kcat	  is	  the	  turnover	  
number	  or	  the	  catalytic	  rate	  of	  the	  enzyme;	  Km	  is	  the	  Michaelis	  constant	  and	  characterizes	  an	  enzyme’s	  approximate	  affinity	  
for	  substrate.	  	  	  	  	  	  	  	  
	  	   	   Ki	  (nM)	  









OCH2O-­‐	   0.0008	   0.034	   0.104	   0.006	  
KY-­‐25	   4-­‐OCH3	   0.0002	   0.001	   0.134	   0.010	  
KY-­‐29	   4-­‐NH2	   0.0050	   0.034	   0.022	   0.134	  
DRV	   4-­‐NH2	   0.0050	   0.025	   0.024	   0.240	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